Questions and Replies

Filter by year

21 April 2023 - NW893

Profile picture: Wilson, Ms ER

Wilson, Ms ER to ask the Minister of Health

(1)Whether he will furnish Mrs E R Wilson with the approved (a) Fraud Prevention Plan and (b) Whistle Blowing Policy Statement of his department; if not, why not; if so, what are the relevant details; (2) on what date was the Fraud Prevention Plan and Whistle Blowing Policy Statement (a) adopted and (b) implemented nationally and in each province; (3) what is the strategy of his department to protect whistle blowers; (4) whether the specified strategy has been adopted (a) nationally and (b) in each province; if not, why not; if so, what are the relevant details; (5) whether he will furnish Mrs E R Wilson with a full report on the outcomes of the strategy to protect whistle blowers in (a) the national department and (b) each provincial department?

Reply:

1. (a) Yes, such a plan and policy statement exists as part of departmental policy framework in instances of fraud and corruption which remain a constant threat to public trust and confidence;

(b) The policy plan and whistle-blowing statement are indeed part of the policy implementation process wherein once developed, they get reviewed to keep with developments in government programmes and legislation from time to time. Dates of adoption and endorsement vary at operational level, for instance endorsement at the National Department was approved on 11 February 2022.

2. Each province has its own policies based on national policy statements as adopted, and vary on dates as developed, reviewed and adopted, according to the existing risk management and prevention as an integral part of strategic management of each province, and are available for scrutiny when so needed.

3. The National Department of Health is currently working with other stakeholders to conduct risk assessment that will determine whether there is need for whistle-blower protection or to strengthen the current exiting measures and mechanisms in Government. Thereafter the outcome will determine the way forward.

4. There are a number of strategies that exist based on national laws and policy frameworks, which get considered when policies are developed and reviewed when necessary and such will vary from time to time, such as the current collaboration the National Department of Health is involved in to enhance the current processes through assessment of risk.

5. It is common practice that upon finalizing any collaborative assignment, it is incumbent and becomes essential that the National Department of Health and its stakeholders share the good practice through available mechanisms by adopting a comprehensive approach to benefit the public and interested parties.

END.

20 April 2023 - NW1201

Profile picture: Wilson, Ms ER

Wilson, Ms ER to ask the Minister of Health

What is the total number of (a) deaths that are caused by (i) obesity and (ii) obesityrelated illnesses annually, (b) persons who have been diagnosed with diabetes since 1 January 2023 and (c) persons who are suffering from hypertension currently?

Reply:

a) (i) Causes of death are statistically derived from death certificates. Obesity will be one of the underlying causes of a health condition that does not appear on the death certificate and therefore a distinct number of deaths caused by obesity is not available. It was observed during the COVID-19 surges that there was link between obesity and deaths.

(ii) Obesity is one of the risk factors for diabetes and hypertension and statistics for these two conditions are provided below.

b) According to the DHIS report, the total number of persons who have been diagnosed with diabetes since 1 January to 28 February 2023 is 46 330.

c) Statistics for hypertension is not collected routinely. We make use of surveys to guide planning and decision making in this regard. According to the SA Demographic and Health Survey 2016, the prevalence for males 15 years and above is 44% and for females of the same age category is 46%.

END.

20 April 2023 - NW1197

Profile picture: Clarke, Ms M

Clarke, Ms M to ask the Minister of Health

What total number of trauma cases have been recorded as (a) crush injury patients and/or (b) crush syndrome patients in (i) public and (ii) private healthcare facilities in each province (aa) in (aaa) 2019, (bbb) 2020, (ccc) 2021 and (ddd) 2022 and (bb) since 1 January2023?

Reply:

(a)(b)(i)(ii) Public health facilities have not been routinely collecting data classified as crush injury and crush syndrome. However, the National Indicator Datasets(NIDS) started collecting information in 2020 on trauma. This data is classified as Accident and Emergency (Casualty) and Trauma unit headcount – Emergency; and Accident and Emergency (Casualty) unit headcount - non-Emergency.

Table1 below indicate overall data on Accidents and Emergency and Trauma Unit headcount for both -Emergency and Non-Emergency by Province

Table 1: Accident and Emergency (Casualty)and Trauma Unit headcount for both emergency and non-emergency from April 2020 to March 2023.

Province

Item

April 2020 to March 2021

April 2021 to March 2022

April 2022 to March 2023

Eastern Cape

Accident and Emergency (Casualty) and Trauma unit headcount - Emergency

268 810

305 553

299 033

Eastern Cape

Accident and Emergency (Casualty) unit headcount - non-Emergency

241 718

972 401

263 069

Free State

Accident and Emergency (Casualty) and Trauma unit headcount - Emergency

108 553

125 891

125 269

Free State

Accident and Emergency (Casualty) unit headcount - non-Emergency

207 144

211 880

200 482

Gauteng

Accident and Emergency (Casualty) and Trauma unit headcount - Emergency

512 255

610 102

583 984

Gauteng

Accident and Emergency (Casualty) unit headcount - non-Emergency

252 813

343 101

421 900

KwaZulu-Natal

Accident and Emergency (Casualty) and Trauma unit headcount - Emergency

381 960

405 307

409 092

KwaZulu-Natal

Accident and Emergency (Casualty) unit headcount - non-Emergency

492 142

607 715

637 989

Limpopo

Accident and Emergency (Casualty) and Trauma unit headcount - Emergency

244 131

291 818

280 911

Limpopo e

Accident and Emergency (Casualty) unit headcount - non-Emergency

241 488

277 484

235 426

Mpumalanga

Accident and Emergency (Casualty) and Trauma unit headcount - Emergency

211 346

244 998

243 611

Mpumalanga

Accident and Emergency (Casualty) unit headcount - non-Emergency

121 188

173 050

146 162

Northern Cape

Accident and Emergency (Casualty) and Trauma unit headcount - Emergency

65 657

69 208

65 665

Northern Cape

Accident and Emergency (Casualty) unit headcount - non-Emergency

102 883

111 587

115 623

Northwest

Accident and Emergency (Casualty) and Trauma unit headcount - Emergency

110 555

123 935

113 856

Northwest

Accident and Emergency (Casualty) unit headcount - non-Emergency

137 592

152 883

125 648

Western Cape

Accident and Emergency (Casualty) and Trauma unit headcount - Emergency

736 083

885 693

906 388

Western Cape

Accident and Emergency (Casualty) unit headcount - non-Emergency

 

 

 

National Total

 

4 436 318

5 912 606

5 174 108

Note: data for Western Cape for non -emergency not available

(a)(b)(i)(ii) Data has been requested from the private health care facilities and is not readily available. This will be made available to the honourable upon receipt.

The NIDS has been reviewed to start collecting data from 2023 classified as:

  1. Sport related trauma – new
  2. Pedestrian vehicle accident – new
  3. Motor vehicle accident – new

However, the crush syndrome medically defined as “the systemic manifestations” resulting from crush injury, which can result in organ dysfunction (predominantly acute kidney injury, but multisystem organ injury can also occur), or death is not included in the NIDS.

END.

20 April 2023 - NW1200

Profile picture: Wilson, Ms ER

Wilson, Ms ER to ask the Minister of Health

With reference to the reply by the Minister of Finance to question 2330 on 6 July 2022, what are the details of (a) the amount of the Health Promotion Levy that was allocated to his department, (b) the amount that has been spent on the various health programmes and (c)(i) each of the specified programmes, (ii) the amount that has been spent on each programme and (iii) strides that each of the programmes has made in improving health in the Republic

Reply:

a) The allocated amount was R48 366 000 in 2022/23

b) R24 437 000 was spent in 2022/23.

c) (i)&(ii) The programme named Chronic Diseases Disabilities & Geriatrics spent R24 437 million on health promotion activities which aim to promote wellness, reduce the common risk factors underlying the priority Non-Communicable Diseases as well as to screen for these NCDs and link persons to care.

(iii) The following strides are made:

  • In 2021 PRICELESS reported evidence-based gains from the Health Promotion Levy (HPL), including
    • The national urban household purchases of taxable beverages by volume fell by 51% (Kantar) with a 29 % decrease in sugar intake.
    • In a self-reported Langa survey of young adults ( 18- 39 y), on taxable beverages showed a 37% reduction by volume and 31% decrease in sugar intake.
    • In a Soweto Study of teenagers, young adults, and older adults, the frequency of Sugar Sweetened Beverages intake amongst heavy consumers fell from 10 beverages per week pre HPL to 4 beverages per week one year post HPL.
  • In 2022, the Department approved the National Strategic Plan for the Prevention and Control of Non-Communicable Diseases 2022 – 2027 (NSP NCDs) which adopts an integrated person centered approach and is inclusive of population level interventions.

The NSP NCDs aims to promote wellness, reduce modifiable risk behaviour, enhance management and control of non-communicable diseases in particular hypertension and diabetes and empower communities, patients and their families.

  • The 2022/23 Annual Performance Quarter 1 to Quarter 4 Reports confirm increased health seeking behaviour as the total screened for diabetes for Q1 was 2 550 479 which increased to 18 838 794 in Q4. Total screened for hypertension for Q1 was 2 654 572 which increased to 19 270 634 in Q4.
  • The Health Promotion Levy was implemented in 2018. Strides in terms of health outcomes manifests in the long-term (at least 10 years), since long established behavioural practices that contribute to ill-health, takes time to reverse.

END.

18 April 2023 - NW1196

Profile picture: Clarke, Ms M

Clarke, Ms M to ask the Minister of Health

What is the total number of emergency beds that were taken up by cases relating to vigilantism, mob and/or community justice in each province (a) in (i) 2020 and (ii) 2021 and (b) since 1 January 2023?

Reply:

In terms of the National Indicator Dataset, the hospital beds are classified according to disciplines in which patients are admitted. The Department of Health does not have record of beds that were taken up by cases relating to vigilantism, mob and/or community justice in all provinces.

END.

18 April 2023 - NW1198

Profile picture: Clarke, Ms M

Clarke, Ms M to ask the Minister of Health

What is the (a) total number of children who died in public health facilities in each province since 1 January 2013, (b) detailed breakdown of the reasons for each death and (c) number of deaths that were due to unnatural causes?

Reply:

a) Total number of children (0 – 59 months ) who died in public health facilities in each province since 1 January 2013 to December 2022 (ten years period)

Table1: Children who died in public health facilities by province since 1 January 2013 to December 2022 (ten years period)

Organisation unit name

Value

Eastern Cape

25 189

Free State

10 189

Gauteng

38 243

KwaZulu-Natal

38 711

Limpopo

24 744

Mpumalanga

14 226

Northern Cape

5 107

North West

10 300

Western Cape

11 736

Source DHIS

(b) Detailed breakdown of the reasons for each death

Provision of individual cause of children’s death to the house contravenes section35 of the Protection of personal information Act (POPIA), aggregated data on common causes of deaths in children are diarrhoea and pneumonia, including the underlying causes such as severe and moderate acute malnutrition, are collected routinely through the district health information system.

Table 2: Causes and underlying causes of deaths from 1st January 2013 to 31st December 2022

Data name

TOTAL

Pneumonia death under 5 years

10,216

Diarrhoea death under 5 years

9491

Moderate acute malnutrition death under 5 years

1410

Severe acute malnutrition death under 5 years

11172

Source DHIS

(c) Number of deaths that were due to unnatural causes?

Number of child deaths due to unnatural causes in public health facilities may not project accurate picture across the country as final causes are documented following the forensic report analysis. Statistics South Africa, Home Affairs and South African Police Service provides accurate information as shown in the table below.

Table 7: Non-natural deaths from 2013 to 2018

Year

Non-natural deaths

% under-5 deaths

2013

2 452

7.0

2014

2 496

7.3

2015

2 509

7.9

2016

2 364

8.3

2017

2 0 4

7.9

2018

2 199

8.4

  Source: StatsSA

 

END.

18 April 2023 - NW1199

Profile picture: Wilson, Ms ER

Wilson, Ms ER to ask the Minister of Health

Whether the National Health Laboratory Service currently has a permanent (a) Chief Financial Officer, (b) Head of Supply Chain, (c) Facilities Manager and (d) Chief Information Officer; if not, (i) for what period has each position been vacant on a permanent basis and (ii) on what date will each position be filled on a permanent basis; if so, what are the relevant details in each case?

Reply:

The NHLS has confirmed that all four positions are filled with the following specific positions details:

a) The Chief Financial Officer was appointed on a five-year contract: The appointment was effective from 01 January 2023.

b) A permanent Head of Supply Chain was appointed: The appointment was effective from 01 August 2022.

c) A permanent Facilities Manager was appointed: The appointment was effective from 01 August 2018.

d) The Chief Information Officer was appointed on a five-year contract: The appointment was effective from 01 January 2020.

END.

18 April 2023 - NW1114

Profile picture: Mkhonto, Ms C N

Mkhonto, Ms C N to ask the Minister of Health

What criteria are used to hire Chief Executive Officers in the provincial departments of Health, especially in Gauteng, as processes in the recruitment process seem to differ between provinces?

Reply:

The process in the recruitment of Chief Executive Officers (CEOs) is not different between Provinces. As all appointments of CEOs across provinces are guided by the Policy on the Management of Public Hospitals that amongst others, makes provision for the criteria pertaining to minimum qualifications, relevant experience and generic qualities required for appointment to the position of hospital CEO (at all levels). This was introduced by Minister of Health in terms of sections 3(1)(c) and 23(1) of National Health Act, 2003, (Act No. 61 of 2003), after consultation with the National Health Council in August 2011.

In line with the above Policy, the Gauteng Provincial Department of Health has informed the Minister that the Chief Executive Officer positions in the Province, are advertised in the National Media (newspaper) and the e-Recruitment platform (Gauteng professional job centre)

The selection process entails the interviews, presentation on the technical exercise prepared by the Selection Committee. Recommended candidates are subjected to the Senior Management Service competency assessment or developmental assessment and vetting processes depending on the level of the position. The department conducts reference checks from the referees provided and conduct suitability checks with the current and previous employers. The recommended candidates are also required to complete Security Vetting Forms, a process facilitated by the State Security Agency.6 The outcome of the above processes is considered by the Executive Authority (EA) in appointing Chief Executive Officers (CEO).

END.

18 April 2023 - NW1135

Profile picture: Hlengwa, Ms MD

Hlengwa, Ms MD to ask the Minister of Health

Considering that in the second Annual Mental State of the World Report from Sapien Labs, the Republic scored the lowest average score on the mental health wellbeing scale, what plans does his department have in place to (a) join collaborative campaigns such as the #breakingstigma campaign (details furnished) and/or (b) initiate its own mental health campaigns?

Reply:

The report titled, The Mental State of the World in 2022 (third report), from Sapiens Labs, is based on responses from 407,959 across 64 countries. The second report of 2021 has an equally small sample size of 223,087 respondents across 34 countries. The reports do not indicate how many persons responded per country, however, the sample size of these reports represent a very small fraction of the population of the countries from which respondents were sourced. Even if the total number of respondents were from South Africa only, the sample size is still too small and the results of the reports can therefore not be generalized to the entire population of South Africa. We nevertheless provide a response to the honourable member’s questions.

a) The Department has prioritised mental health in view of the burden of diseases associated with mental illnesses. The upstream determinants of mental health cut across responsibilities and mandates of a number of sectors and the NDoH collaborates with other Departments in Government and NGOs such as Higher Health and the SA Federation for Mental Health on a number of aspects related to promoting mental health including activities aimed at combating stigma.

b) Future plans are aimed at expanding prevention, advocacy and stigma combating activities. This will entail working with a wider range of partners in line with the strategies articulated in the National Strategic Plan for Non-Communicable Diseases 2022-2027 and the Mental Health Policy Framework and Strategy 2023-2030.

END.

11 April 2023 - NW894

Profile picture: Wilson, Ms ER

Wilson, Ms ER to ask the Minister of Health

(1)Whether his department has taken any steps to blacklist the companies whose transactions with the Tembisa Hospital were flagged by the murdered whistle blower, Ms Babita Deokaran; (2) (a) which companies have been blacklisted in each province and (b) what were the reasons for blacklisting each company since 1 January 2020 in each case?

Reply:

1. The Tembisa Hospital matter is still under investigation by the Special Investigating Unit (SIU). Once the investigation has been finalized, the Department will comply with any directives issued by the SIU. If such directives includes the blacklisting of the companies referred to, the Department will implement the recommendation.

2. (a) and (b) - No Department within the Public Health Sector have blacklisted any company since 01 January 2020 to date.

END.

11 April 2023 - NW855

Profile picture: Tito, Ms LF

Tito, Ms LF to ask the Minister of Health

Whether he has been informed that only one ambulance is available between Kakamas and Keimoes in the Northern Cape; if not, why not; if so, what is the reason for this?

Reply:

Yes, I have been informed that there is one ambulance based in Keimoes, however, an ambulance that is based in Kakamas also responds to Keimoes when needed. It must be noted that these are remote areas with low population density and low call out rates.

END.

11 April 2023 - NW895

Profile picture: Wilson, Ms ER

Wilson, Ms ER to ask the Minister of Health

(1)Whether he will furnish Mrs E R Wilson with a list of all essential medicines for which there (a) is only one supplier and (b) are multiple suppliers; if not, why not, in each case; if so, what are the relevant details in each case; (2) what are the reasons that the Government only has one supplier for essential medicines that have a single supplier; (3) whether his department will consider finding multiple suppliers for essential medications; if not, why not; if so, what (a) progress has his department made in this regard and (b) are the further relevant details?

Reply:

(1) The list of contacted suppliers is available on the National Department of Health’s website, at the following url: https://www.health.gov.za/tenders/

Click on the tab: Master Health Product List.

  1. See attached document with list of essential medicines where contracts were awarded to one supplier only on pages 1–21;
  2. See attached document with list of essential medicines where contracts were awarded to more than supplier only from page 22 onwards.

(2) The decision to award a contract to one supplier only is informed by a number of factors including the following:

  • The product is only available from one supplier registered with SAHPRA (i.e. sole supplier);
  • During the contracting process, a bid was only received from one registered supplier even if there are other suppliers in the market;
  • The estimated tender volumes are too low to justify award to more than one supplier as this decreases the benefits derived from economies of scale.

(3) It is the standard practice of the Department of Health to award more than one supplier in to manage risks related to supply challenges for certain strategic products that are important for successful implementation of public health programmes.

The decision to award contracts to more than one supplier depends on factors such as the following:

  • The estimated tender volumes are high because of high disease burden, as in the case of first line antiretrovirals used in the management of HIV;
  • The highest scoring bidder does not have the capacity to meet estimated tender volumes and their inability to meet demand during a contract period would result in a supply challenge;
  • There is a risk to public health if the medicine is not available.

END.

Annexure 1

Medicine Description (More than one contracted supplier)

  • Abacavir; 20mg/ml; Solution; 240 ml
  • Allopurinol; 300mg; Tablet; 30 Tablets
  • Amitriptyline; 25mg; Tablet; 28 Tablets
  • Amlodipine; 10mg; Tablet; 28 Tablets
  • Amlodipine; 5mg; Tablet; 28 Tablets
  • Amoxicillin, Clavulanic Acid; 125mg/5ml, 31.25mg/5ml; Suspension; 100 ml
  • Amoxicillin, Clavulanic Acid; 250mg, 125mg; Tablet; 15 Tablets
  • Amoxicillin, Clavulanic Acid; 250mg/5ml, 62.5mg/5ml; Suspension; 100 ml
  • Amoxicillin, Clavulanic Acid; 875mg, 125mg; Tablet; 10 Tablets
  • Amoxicillin; 125mg/5ml; Suspension; 100 ml
  • Amoxicillin; 250mg/5ml; Suspension; 100 ml
  • Amoxicillin; 250mg; Capsule; 15 Capsules
  • Amoxicillin; 500mg; Capsule; 15 Capsules
  • Ampicillin; 250mg; injection; 1 Injection
  • Ampicillin; 500mg; injection; 1 Injection
  • Aspirin; 300mg; tablet, scored; 14 Tablets
  • Atenolol; 50mg; Tablet; 30 Tablets
  • Atorvastatin; 10mg; Tablet; 28 Tablets
  • Atropine; 1mg/ml; injection; 1 ml
  • Atropine; 500mcg/ml; injection; 1 ml
  • Azithromycin; 500mg; Tablet; 2 Tablets
  • Azithromycin; 500mg; Tablet; 3 Tablets
  • Calcium Carbonate, Glycine; 420mg, 180mg; Tablet; 168 Tablets
  • Calcium Carbonate; 500mg; Tablet; 10 Tablets
  • Calcium Carbonate; 500mg; Tablet; 30 Tablets
  • Carbamazepine; 200mg; Tablet; 56 Tablets
  • Carbamazepine; 200mg; Tablet; 84 Tablets
  • Cefazolin; 1g; injection; 1 Injection
  • Cefazolin; 500mg; injection; 1 Injection
  • Ceftriaxone; 1g; injection; 1 Injection
  • Ceftriaxone; 250mg; injection; 1 Injection
  • Ceftriaxone; 500mg; injection; 1 Injection
  • Cetirizine; 10mg; Tablet; 28 Tablets
  • Chlorphenamine; 2mg/5ml; Syrup; 50 ml
  • Ciprofloxacin; 500mg; Tablet; 10 Tablets
  • Citalopram; 20mg; Tablet; 28 Tablets
  • Clotrimazole; 1%; Cream; 20 g
  • Clotrimazole; 500mg/50g; cream, vaginal; 50 g
  • Dexamethasone; 4mg/ml; injection; 1 ml
  • Diclofenac; 75mg/3ml; Injection; 3 ml
  • Dolutegravir; 50mg; Tablet; 30 Tablets
  • Doxazosin; 4mg; Tablet; 30 Tablets
  • Doxycycline; 100mg; Tablet; 14 Tablets
  • Efavirenz; 200mg; Tablet; 84 Tablets
  • Efavirenz; 600mg; Tablet; 28 Tablets
  • Enalapril; 10mg; Tablet; 28 Tablets
  • Enalapril; 20mg; Tablet; 30 Tablets
  • Enalapril; 5mg; Tablet; 28 Tablets
  • Epinephrine (Adrenaline); 1mg/ml; injection; 1 ml
  • Fentanyl; 100mcg/2ml; injection; 2 ml
  • Ferrous Sulfate Co; 170mg; Tablet; 28 Tablets
  • Flucloxacillin; 250mg; Capsule; 20 Capsules
  • Flucloxacillin; 250mg; Capsule; 40 Capsules
  • Fluoxetine; 20mg; Capsule; 28 Capsules
  • Folic Acid; 5mg; Tablet; 28 Tablets
  • Furosemide; 40mg; Tablet; 28 Tablets
  • Furosemide; 40mg; Tablet; 56 Tablets
  • Furosemide; 40mg; Tablet; 84 Tablets
  • Glibenclamide; 5mg; Tablet; 28 Tablets
  • Glibenclamide; 5mg; Tablet; 56 Tablets
  • Glimepiride; 1mg; Tablet; 28 Tablets
  • Glimepiride; 2mg; Tablet; 28 Tablets
  • Glimepiride; 4mg; Tablet; 28 Tablets
  • Hydrochlorothiazide; 25mg; Tablet; 28 Tablets
  • Hydrocortisone; 100mg/2ml; injection; 2 ml
  • Ibuprofen; 200mg; Tablet; 15 Tablets
  • Ibuprofen; 200mg; Tablet; 42 Tablets
  • Ibuprofen; 200mg; Tablet; 84 Tablets
  • Ibuprofen; 400mg; Tablet; 15 Tablets
  • Isoniazid; 100mg; Tablet; 28 Tablets
  • Isoniazid; 300mg; Tablet; 28 Tablets
  • Lamivudine, Abacavir, Dolutegravir; 300mg, 600mg, 50mg; Tablet; 28 Tablets
  • Lamivudine, Abacavir; 300mg, 600mg; Tablet; 28 Tablets
  • Lamivudine, Abacavir; 60mg, 120mg; Tablet; 28 Tablets
  • Lamivudine; 10mg/ml; Solution; 240 ml
  • Lamivudine; 150mg; Tablet; 56 Tablets
  • Lansoprazole; 30mg; Capsule; 28 Capsules
  • Loperamide; 2mg; Tablet; 6 Tablets
  • Lopinavir, Ritonavir; 200mg, 50mg; Tablet; 112 Tablets
  • Metformin; 500mg; Tablet; 56 Tablets
  • Metformin; 500mg; Tablet; 84 Tablets
  • Metformin; 850mg; Tablet; 28 Tablets
  • Metformin; 850mg; Tablet; 56 Tablets
  • Metformin; 850mg; Tablet; 84 Tablets
  • Metoclopramide; 10mg; Tablet; 10 Tablets
  • Metronidazole; 400mg; Tablet; 14 Tablets
  • Metronidazole; 400mg; Tablet; 5 Tablets
  • Metronidazole; 500mg/100ml; injection; 100 ml
  • Midazolam; 15mg/3ml; injection; 3 ml
  • Midazolam; 5mg/5ml; injection; 5 ml
  • Morphine; 10mg/ml; injection; 1 ml
  • Morphine; 15mg/ml; injection; 1 ml
  • Omeprazole; 20mg; Capsule; 14 Capsules
  • Oxytocin; 10IU/ml; injection; 1 ml
  • Pantoprazole; 20mg; Tablet; 30 Tablets
  • Paracetamol; 500mg; Tablet; 100 Tablets
  • Paracetamol; 500mg; Tablet; 20 Tablets
  • Pethidine; 100mg/2ml; injection; 2 ml
  • Pethidine; 50mg/ml; injection; 1 ml
  • Prednisone; 5mg; Tablet; 28 Tablets
  • Rifampicin, Isoniazid; 150mg, 75mg; Tablet; 56 Tablets
  • Rifampicin, Isoniazid; 150mg, 75mg; Tablet; 84 Tablets
  • Rifampicin, Isoniazid; 300mg, 150mg; Tablet; 56 Tablets
  • Rifampicin, Pyrazinamide, Ethambutol, Isoniazid; 150mg, 400mg, 275mg, 75mg; Tablet; 112 Tablets
  • Rifampicin, Pyrazinamide, Ethambutol, Isoniazid; 150mg, 400mg, 275mg, 75mg; Tablet; 56 Tablets
  • Rifampicin, Pyrazinamide, Ethambutol, Isoniazid; 150mg, 400mg, 275mg, 75mg; Tablet; 84 Tablets
  • Salbutamol; 100mcg; Inhaler; 200 Doses
  • Simvastatin; 10mg; Tablet; 28 Tablets
  • Simvastatin; 20mg; Tablet; 28 Tablets
  • Sodium Chloride; 0.9%; injection; 10 ml
  • Spironolactone; 25mg; Tablet; 28 Tablets
  • Sulfamethoxazole, Trimethoprim; 200mg/5ml, 40mg/5ml; Suspension; 100 ml
  • Sulfamethoxazole, Trimethoprim; 400mg, 80mg; Tablet (Co-trimoxazole); 28 Tablets
  • Sulfamethoxazole, Trimethoprim; 400mg, 80mg; Tablet (Co-trimoxazole); 56 Tablets
  • Tenofovir, Emtricitabine, Efavirenz; 300mg, 200mg, 600mg; Tablet; 28 Tablets
  • Tenofovir, Emtricitabine, Efavirenz; 300mg, 200mg, 600mg; Tablet; 84 Tablets
  • Tenofovir, Emtricitabine; 300mg, 200mg; Tablet; 28 Tablets
  • Tenofovir, Lamivudine, Dolutegravir; 300mg, 300mg, 50mg; Tablet; 84 Tablets
  • Tenofovir, Lamivudine, Dolutegravir; 300mg, 300mg, 50mg; Tablet; 28 Tablets
  • Tramadol; 50mg; Capsule; 100 Capsules
  • Tramadol; 50mg; Capsule; 20 Capsules
  • Vitamin B1 (Thiamine); 100mg; Tablet; 28 Tablets
  • Vitamin B6 (Pyridoxine); 25mg; Tablet; 28 Tablets

Annexure 2

Medicine Description (One contracted supplier)

  • Abacavir; 300mg; Tablet; 56 Tablets
  • Abacavir; 60mg; Tablet, dispersible; 56 Tablets
  • Acetazolamide; 250mg; Tablet; 100 Tablets
  • Acetazolamide; 250mg; Tablet; 30 Tablets
  • Acetic Acid; Liquid; 500 ml
  • Acetylcysteine; 200mg/ml; injection; 10 ml
  • Acetylcysteine; 200mg; Tablet; 20 Tablets
  • Aciclovir; 200mg; Tablet, dispersible; 25 Tablets
  • Aciclovir; 250mg; injection; 1 Injection
  • Aciclovir; 400mg; Tablet, dispersible; 70 Tablets
  • Adenosine; 6mg/2ml; injection; 2 ml
  • Albendazole; 400mg; Tablet; 1 Tablet
  • Albumin, Human, Normal; 20%; Infusion (parenteral); 100 ml
  • Albumin, Human, Normal; 20%; Infusion (parenteral); 50 ml
  • Alfentanil; 1mg/2ml; injection; 2 ml
  • Allopurinol; 100mg; Tablet; 100 Tablets
  • Allopurinol; 100mg; Tablet; 28 Tablets
  • Allopurinol; 100mg; Tablet; 56 Tablets
  • Alprazolam; 0.5mg; Tablet; 30 Tablets
  • Alprostadil; 500mcg/ml; injection; 1 ml
  • Alteplase; 50mg; injection; 1 Injection
  • Aluminium hydroxide; 300mg/5ml; Suspension; 500 ml
  • Amikacin Sulph; 100mg/2ml; injection; 2 ml
  • Amikacin Sulph; 250mg/2ml; injection; 2 ml
  • Amikacin Sulph; 500mg/2ml; injection; 2 ml
  • Aminophylline; 250mg/10ml; injection; 10 ml
  • Amiodarone; 150mg/3ml; injection; 3 ml
  • Amiodarone; 200mg; Tablet; 30 Tablets
  • Amisulpride; 200mg; Tablet; 30 Tablets
  • Amisulpride; 50mg; Tablet; 30 Tablets
  • Amitriptyline; 10mg; Tablet; 100 Tablets
  • Amitriptyline; 10mg; Tablet; 28 Tablets
  • Amitriptyline; 25mg; Tablet; 100 Tablets
  • Amitriptyline; 25mg; Tablet; 168 Tablets
  • Amitriptyline; 25mg; Tablet; 500 Tablets
  • Amitriptyline; 25mg; Tablet; 56 Tablets
  • Amitriptyline; 25mg; Tablet; 84 Tablets
  • Amoxicillin, Clavulanic Acid; 1,000mg, 200mg; injection; 1 Injection
  • Amoxicillin, Clavulanic Acid; 500mg, 100mg; injection; 1 Injection
  • Amoxicillin/Clavulanic Acid; 600mg/42.9mg; Suspension; 100 ml
  • Amoxicillin; 250mg; Capsule; 100 Capsules
  • Amoxicillin; 500mg; Capsule; 100 Capsules
  • Anastrozole; 1mg; Tablet; 28 Tablets
  • Aqueous; Cream; 100 g
  • Aqueous; Cream; 500 g
  • Aripiprazole; 10mg; Tablet; 30 Tablets
  • Aripiprazole; 15mg; Tablet; 30 Tablets
  • Aripiprazole; 5mg; Tablet; 30 Tablets
  • Artemether, Lumefantrine; 20mg, 120mg; Tablet; 24 Tablets
  • Artesunate; 60mg; injection; 1 Injection
  • Aspirin; 300mg; Tablet; 96 Tablets
  • Atazanavir, Ritonavir; 300mg, 100mg; Tablet; 28 Tablets
  • Atazanavir; 200mg; Capsule; 60 Capsules
  • Atazanavir; 300mg; Capsule; 30 Capsules
  • Atenolol; 100mg; Tablet; 28 Tablets
  • Atenolol; 25mg; Tablet; 28 Tablets
  • Atorvastatin; 20mg; Tablet; 30 Tablets
  • Atorvastatin; 40mg; Tablet; 30 Tablets
  • Atracurium; 25mg/2.5ml; injection; 2.5 ml
  • Atracurium; 50mg/5ml; injection; 5 ml
  • Atropine; 1%; Drop, Eye; 5 ml
  • Azathioprine; 50mg; Tablet; 100 Tablets
  • Balanced Salt; solution, ophthalmic; 15 ml
  • Balanced Salt; solution, ophthalmic; 500 ml
  • Barium Sulfate With Suspending Agent; 4.6%; Suspension; 225 ml
  • Barium Sulfate With Suspending Agent; 98g/100g; Powder; 340 g
  • Barium Sulfate; BP; Suspension; 1 Kit
  • Beclometasone; 100mcg; Inhaler; 200 Doses
  • Beclometasone; 100mcg; Inhaler; SERIES; 200 Doses
  • Beclometasone; 200mcg; Inhaler; 200 Doses
  • Beclometasone; 50mcg; Inhaler; 200 Doses
  • Beclometasone; 50mcg; Inhaler; SERIES; 200 Doses
  • Beclometasone; 50mcg; Spray, Nasal; 150 Doses
  • Benzoin Co; Tincture; 100 ml
  • Benzoin Co; Tincture; 20 ml
  • Benzydamine, Chlorhexidine; 22.5mg/15ml, 18mg/15ml; Mouthwash; 200 ml
  • Benzyl Benzoate; 25%; Liquid; 100 ml
  • Betamethasone Disodium Phosphate; 4mg/ml; injection; 1 ml
  • Betamethasone Valerate; 0.1%; Cream; 15 g
  • Betamethasone Valerate; 0.1%; Cream; 50 g
  • Betamethasone Valerate; 0.1%; Cream; 500 g
  • Betamethasone; 500mcg; Tablet; 100 Tablets
  • Betamethasone; 500mcg; Tablet; 20 Tablets
  • Betaxolol; 2.5mg/ml; Drop, Eye; 5 ml
  • Betaxolol; 5mg/ml; Drop, Eye; 5 ml
  • Bevacizumab; 100mg/4ml; injection; 4 ml
  • Bezafibrate; 400mg; Tablet; 30 Tablets
  • Bimatoprost; 0.3mg/ml; Drop, Eye; 3 ml
  • Biperiden; 2mg; Tablet; 100 Tablets
  • Biperiden; 5mg/ml; injection; 1 ml
  • Bisacodyl; 10mg; Suppository; 10 Suppositories
  • Bleomycin; 15IU; injection; 1 Injection
  • Bortezomib; 3.5mg; injection; 10 ml
  • Botulinum Toxin, Type A, Lyophilised; 100IU; injection; 1 Injection
  • Brimonidine; 1.5mg/ml; Drop, Eye; 5 ml
  • Brimonidine; 2mg/ml; Drop, Eye; 5 ml
  • Bromocriptine; 2.5mg; Tablet; 30 Tablets
  • Budesonide, Formoterol; 160mcg, 4.5mcg; Inhaler; 60 Doses
  • Budesonide, Formoterol; 320mcg, 9mcg; Inhaler; 60 Doses
  • Bupivacaine, Adrenaline; 5mg/ml, 5mcg/ml; injection; 20 ml
  • Bupivacaine, Dextrose; 5mg, 72.7mg; injection; 4 ml
  • Bupivacaine; 5mg/ml; injection (Spinal); 10 ml
  • Bupivacaine; 5mg/ml; injection (Spinal); 4 ml
  • Busulfan; 2mg; Tablet; 100 Tablets
  • Caffeine; 20mg/ml; injection; 1 ml
  • Calamine; Lotion; 100 ml
  • Calcium Folinate; 100mg; injection; 1 Injection
  • Calcium Folinate; 15mg; Tablet; 10 Tablets
  • Calcium Folinate; 300mg; injection; 1 Injection
  • Calcium Gluconate; 10%; injection; 10 ml
  • Capecitabine; 150mg; Tablet; 60 Tablets
  • Capecitabine; 500mg; Tablet; 120 Tablets
  • Captopril; 25mg; Tablet; 60 Tablets
  • Carbamazepine; 100mg/5ml; Suspension; 250 ml
  • Carbamazepine; 200mg; Tablet; 100 Tablets
  • Carbamazepine; 200mg; Tablet; 28 Tablets
  • Carbimazole; 5mg; Tablet; 100 Tablets
  • Carboplatin; 150mg/15ml; injection; 15 ml
  • Carboplatin; 450mg/45ml; injection; 45 ml
  • Carvedilol; 12.5mg; Tablet; 28 Tablets
  • Carvedilol; 25mg; Tablet; 30 Tablets
  • Cefalexin; 125mg/5ml; Suspension; 100 ml
  • Cefalexin; 250mg/5ml; Suspension; 100 ml
  • Cefalexin; 250mg; Capsule; 20 Capsules
  • Cefalexin; 500mg; Capsule; 20 Capsules
  • Cefepime; 1g; injection; 1 Injection
  • Cefepime; 2g; injection; 1 Injection
  • Cefotaxime; 1g; injection; 1 Injection
  • Cefotaxime; 500mg; injection; 1 Injection
  • Ceftazidime; 1g; injection; 1 Injection
  • Ceftazidime; 2g; injection; 1 Injection
  • Cetirizine; 1mg/ml; Syrup; 150 ml
  • Chlorambucil; 2mg; Tablet; 25 Tablets
  • Chloramphenicol; 0.5%; Drop, Eye; 10 ml
  • Chloramphenicol; 1%; ointment, eye; 3.5 g
  • Chlorhexidine, Alcohol; 0.5%, 70%; Solution (without emolient); 500 ml
  • Chlorhexidine, Alcohol; 0.5%, 70%; Solution; 50 ml
  • Chlorhexidine; 0.2%; Mouthwash; 200 ml
  • Chlorhexidine; 4%; Solution (Hibiscrub); 500 ml
  • Chlorphenamine; 4mg; Tablet; 10 Tablets
  • Chlorphenamine; 4mg; Tablet; 30 Tablets
  • Chlorpromazine; 100mg; Tablet; 56 Tablets
  • Chlorpromazine; 25mg; Tablet; 56 Tablets
  • Ciclosporin; 100mg/ml; Solution; 50 ml
  • Ciclosporin; 100mg; Capsule; 50 Capsules
  • Ciclosporin; 25mg; Capsule; 50 Capsules
  • Ciclosporin; 50mg; injection; 1 Injection
  • Ciprofloxacin; 100mg/50ml; injection; 100 ml
  • Ciprofloxacin; 250mg/5ml; Suspension; 100 ml
  • Ciprofloxacin; 250mg; Tablet; 10 Tablets
  • Ciprofloxacin; 3mg/ml; Drop, Eye; 5 ml
  • Ciprofloxacin; 400mg/200ml; Infusion (parenteral); 200 ml
  • Cisatracurium; 10mg/5ml; injection; 5 ml
  • Cisatracurium; 5mg/2.5ml; injection; 2.5 ml
  • Cisplatin; 10mg/10ml; injection; 10 ml
  • Cisplatin; 50mg/50ml; injection; 50 ml
  • Citalopram; 10mg; Tablet; 30 Tablets
  • Clarithromycin; 125mg/5ml; Suspension; 60 ml
  • Clarithromycin; 250mg/5ml; Suspension; 60 ml
  • Clarithromycin; 500mg; Tablet; 14 Tablets
  • Clindamycin; 150mg; Capsule; 100 Capsules
  • Clindamycin; 150mg; Capsule; 20 Capsules
  • Clindamycin; 600mg/4ml; injection; 4 ml
  • Clobetasol; 0.05%; Cream; 25 g
  • Clobetasol; 0.05%; Ointment; 25 g
  • Clomifene; 50mg; Tablet; 10 Tablets
  • Clomipramine; 25mg; Tablet; 50 Tablets
  • Clonazepam; 0.5mg; Tablet; 84 Tablets
  • Clonazepam; 2mg; Tablet; 84 Tablets
  • Clopidogrel; 75mg; Tablet; 30 Tablets
  • Clotiapine; 40mg/4ml; injection; 4 ml
  • Clotrimazole; 500mg; Pessary; 1 Pessary
  • Cloxacillin; 250mg; injection; 1 Injection
  • Cloxacillin; 500mg; injection; 1 Injection
  • Clozapine; 100mg; Tablet; 100 Tablets
  • Clozapine; 25mg; Tablet; 100 Tablets
  • Coal Tar; BP; Solution; 500 ml
  • Codeine Phosphate; 30mg; Tablet; 100 Tablets
  • Colchicine; 500mcg; Tablet; 12 Tablets
  • Cyclopentolate, Phenylephrine; 0.2%, 1%; Drop, Eye; 5 ml
  • Cyclopentolate; 1%; Drop, Eye; 15 ml
  • Cyclophosphamide; 1g; injection; 1 Injection
  • Cyclophosphamide; 500mg; injection; 1 Injection
  • Cyclophosphamide; 50mg; Tablet; 50 Tablets
  • Cyproterone, Ethinylestradiol; 2mg, 0.035mg; Tablet; 28 Tablets
  • Cyproterone; 10mg; Tablet; 15 Tablets
  • Cyproterone; 50mg; Tablet; 20 Tablets
  • Dacarbazine; 200mg; injection; 1 Injection
  • Dapsone; 100mg; Tablet; 100 Tablets
  • Darunavir, Ritonavir; 400mg, 50mg; Tablet; 56 Tablets
  • Deferasirox; 250mg; Tablet; 28 Tablets
  • Deferasirox; 500mg; Tablet; 28 Tablets
  • Deferoxamine; 500mg; injection; 1 Injection
  • Desmopressin; 0.1mg; Tablet; 30 Tablets
  • Desmopressin; 0.2mg; Tablet; 30 Tablets
  • Desmopressin; 100mcg/ml; Spray, Nasal; 5 ml
  • Desmopressin; 4mcg/ml; injection; 1 Injection
  • Dexamethasone; 0.1%; Drop, Eye; 5 ml
  • Dextrose In Water; 50%; injection; 20 ml
  • Dextrose In Water; 50%; injection; 50 ml
  • Dextrose Monohydrate; BP; Powder; 500 g
  • Dextrose Monohydrate; BP; Powder; 75 g
  • Dextrose, Electrolyte; 5%; Infusion (parenteral); 1 L
  • Dextrose, Maintelyte; 10%; Infusion (parenteral); 1 L
  • Dextrose, Maintelyte; 5%; Infusion (parenteral); 1 L
  • Dextrose; 10%; Infusion (parenteral); 1 L
  • Dextrose; 5%; Infusion (parenteral); 1 L
  • Dextrose; 5%; Infusion (parenteral); 100 ml
  • Dextrose; 5%; Infusion (parenteral); 200 ml
  • Dextrose; 5%; Infusion (parenteral); 50 ml
  • Dextrose; 50%; Infusion (parenteral); 500 ml
  • Diazepam; 10mg/2ml; injection; 2 ml
  • Diazepam; 5mg; Tablet; 100 Tablets
  • Diazepam; 5mg; Tablet; 14 Tablets
  • Diazoxide; 20mg; Capsule; 100 Capsules
  • Digoxin; 250mcg; Tablet; 30 Tablets
  • Digoxin; 62.5mcg; Tablet; 100 Tablets
  • Dinoprostone; 0.5mg; Tablet; 10 Tablets
  • Dinoprostone; 1mg/3g; Syringe, Prefilled; 3 g
  • Dobutamine; 250mg/20ml; injection; 20 ml
  • Docetaxel; 20mg/ml; injection; 1 ml
  • Docetaxel; 80mg/4ml; injection; 4 ml
  • Dolutegravir; 50mg; tablet, scored; 30 Tablets
  • Dopamine; 200mg/5ml; injection; 5 ml
  • Doxorubicin; 10mg/5ml; injection; 5 ml
  • Doxorubicin; 50mg/25ml; injection; 25 ml
  • Doxycycline; 100mg; Tablet; 100 Tablets
  • Efavirenz; 50mg; Capsule; 28 Capsules
  • Electrolyte No 2 Solution: Na, K, Cl, Mg, Hpo4, Dextrose; injection; 1 L
  • Emulsifying; BP; Ointment; 500 g
  • Enoxaparin; 40mg/0.4ml; Syringe, Prefilled; 0.4 ml
  • Enoxaparin; 60mg/0.6ml; Syringe, Prefilled; 0.6 ml
  • Enoxaparin; 80mg/0.8ml; Syringe, Prefilled; 0.8 ml
  • Epinephrine (Adrenaline); 0.15mg/0.3ml; auto-pen; 0.3 ml
  • Epinephrine (Adrenaline); 0.3mg/0.3ml; auto-pen; 0.3 ml
  • Epirubicin; 10mg/5ml; injection; 5 ml
  • Epirubicin; 50mg/25ml; injection; 25 ml
  • Ergometrine, Oxytocin; 500mcg, 5IU; injection; 1 ml
  • Ertapenem; 1g; injection; 1 Injection
  • Erythropoietin; 10000IU; injection; 1 ml
  • Erythropoietin; 2000IU/0.3ml; Syringe, Prefilled; 1 Syringe, Pre-filled
  • Erythropoietin; 30000IU/0.6ml; Syringe, Prefilled; 1 Syringe, Pre-filled
  • Erythropoietin; 4000IU; injection; 1 ml
  • Erythropoietin; 6000IU; injection; 1 ml
  • Estradiol, Norethisterone Acetate; 1mg, 0.5mg; Tablet; 28 Tablets
  • Estradiol, Norethisterone Acetate; 2mg, 1mg; Tablet; 28 Tablets
  • Estradiol; 1mg; Tablet; 28 Tablets
  • Estradiol; 2mg; Tablet; 28 Tablets
  • Estrogen, Conjugated ; 0.3mg; Tablet; 28 Tablets
  • Ethambutol; 400mg; Tablet; 100 Tablets
  • Ethambutol; 400mg; Tablet; 56 Tablets
  • Ethambutol; 400mg; Tablet; 84 Tablets
  • Ethionamide; 250mg; Tablet; 250 Tablets
  • Ethionamide; 250mg; Tablet; 28 Tablets
  • Ethionamide; 250mg; Tablet; 56 Tablets
  • Ethionamide; 250mg; Tablet; 84 Tablets
  • Etomidate; 20mg/10ml; injection; 10 ml
  • Etonogestrel; 68mg; Implant; 1 Device
  • Etoposide; 100mg; injection (Section 21); 1 Injection
  • Exemestane; 25mg; Tablet; 28 Tablets
  • Fenoterol; 1.25mg/2ml; solution, inhalation; 60 UDVs (2ml)
  • Fentanyl; 500mcg/10ml; injection; 10 ml
  • Ferrous Gluconate; 350mg/5ml; Syrup; 100 ml
  • Ferrous Sulfate Co; 170mg; Tablet; 100 Tablets
  • Ferrous Sulfate Co; 170mg; Tablet; 56 Tablets
  • Ferrous Sulfate Co; 170mg; Tablet; 84 Tablets
  • Filgrastim; 30MU; Syringe, Prefilled; 1 Syringe, Pre-filled
  • Filgrastim; 48MU; Syringe, Prefilled; 1 Syringe, Pre-filled
  • Flucloxacillin; 250mg; Capsule; 100 Capsules
  • Fluconazole; 200mg/100ml; Infusion (parenteral); 100 ml
  • Fluconazole; 200mg; Tablet; 28 Tablets
  • Fluconazole; 50mg/5ml; Suspension; 35 ml
  • Fluconazole; 50mg; Tablet; 14 Tablets
  • Fludarabine; 10mg; Tablet; 20 Tablets
  • Fludarabine; 50mg; injection; 1 Injection
  • Fluocinolone Acetonide; 0.025%; Ointment; 15 g
  • Fluorouracil; 5%; Ointment; 20 g
  • Fluoxetine; 20mg; Capsule; 100 Capsules
  • Flupentixol; 20mg/ml; injection; 1 ml
  • Fluticasone Propionate; 50mcg; Spray, Nasal; 120 Doses
  • Folic Acid; 5mg; Tablet; 100 Tablets
  • Formoterol; 12mcg; Inhaler; 120 Doses
  • Fosfomycin; Granules; 1 Sachet (3g)
  • Furosemide; 10mg/ml; Solution; 100 ml
  • Furosemide; 20mg/2ml; injection; 2 ml
  • Furosemide; 250mg/25ml; injection; 25 ml
  • Furosemide; 40mg; Tablet; 112 Tablets
  • Furosemide; 40mg; Tablet; 250 Tablets
  • Furosemide; 500mg; Tablet; 100 Tablets
  • Furosemide; 50mg/5ml; injection; 5 ml
  • Ganciclovir; 500mg; injection; 1 Injection
  • Gemcitabine; 1g; injection; 1 Injection
  • Gemcitabine; 200mg; injection; 1 Injection
  • Gentamicin; 20mg/2ml; injection; 2 ml
  • Gentamicin; 80mg/2ml; injection; 2 ml
  • Glibenclamide; 5mg; Tablet; 100 Tablets
  • Glibenclamide; 5mg; Tablet; 84 Tablets
  • Glucagon; 1mg; injection; 1 ml
  • Glucometer; Medical device; 1 Device
  • Glycerol; BP; Liquid; 500 ml
  • Glycerol; 0.891ml; Suppository; 12 Suppositories
  • Glycerol; 1.698ml; Suppository; 12 Suppositories
  • Glyco Thymol Co; Mouthwash; 100 ml
  • Glycopyrronium Bromide; 400mcg/2ml; injection; 2 ml
  • Glycopyrronium Bromide; 50mcg; Inhaler; 30 Doses
  • Goserelin; 10.8mg; Syringe, Prefilled; 1 Syringe, Pre-filled
  • Goserelin; 3.6mg; Syringe, Prefilled; 1 Syringe, Pre-filled
  • Granisetron; 1mg; injection; 1 Injection
  • Granisetron; 3mg/3ml; injection; 3 ml
  • Half Darrow With Glucose; 5%; Infusion (parenteral); 200 ml
  • Half Darrow With Glucose; 5%; Infusion (parenteral); 500 ml
  • Haloperidol; 1.5mg; Tablet; 100 Tablets
  • Haloperidol; 5mg; Tablet; 100 Tablets
  • Haloperidol; 5mg; Tablet; 28 Tablets
  • Haloperidol; 5mg; Tablet; 56 Tablets
  • Halothane; Liquid; 250 ml
  • Heparin; 25000IU/5ml; injection; 5 ml
  • Heparin; 5000IU/5ml; injection; 5 ml
  • HUMAN COAGULATION CONCENTRATE COMPLEX: FACTOR VIII COMPLEX 1 000 IU INJECTION, UNIT CONTAINING - A HIGH SPECIFIC FACTOR VIII (FACTOR VIII: C) ACTIVITY - VON WILLEBRAND FACTOR (FACTOR
  • HUMAN COAGULATION CONCENTRATE COMPLEX: FACTOR VIII COMPLEX 500 IU INJECTION, UNIT CONTAINING - A HIGH SPECIFIC FACTOR VIII (FACTOR VIII: C) ACTIVITY - VON WILLEBRAND FACTOR (FACTOR
  • Human Coagulation Factor Concentrate: Activated Prothrombin Complex; 500IU; injection; 1 Injection
  • Human Coagulation Factor Concentrate: Activated Prothrombin Complex; 1,000IU; injection; 1 Injection
  • Human Coagulation Factor Concentrate: Factor Ix Complex; 500IU; injection; 1 Injection
  • Human Coagulation Factor Concentrate: Factor Viia Complex; 100,000IU; injection; 1 Injection
  • Human Coagulation Factor Concentrate: Factor Viia Complex; 250,000IU; injection; 1 Injection
  • Human Coagulation Factor Concentrate: Factor Viia Complex; 50,000IU; injection; 1 Injection
  • Human Coagulation Factor Concentrate: Factor Viii Complex; 1,000IU; injection; 1 Injection
  • Human Coagulation Factor Concentrate: Factor Viii Complex; 300IU; injection; 1 Injection
  • Human Coagulation Factor Concentrate: Factor Viii Complex; 500IU; injection; 1 Injection
  • Hyaluronic Acid; 10mg/ml; Syringe, Prefilled; 0.4 ml
  • Hyaluronic Acid; 10mg/ml; Syringe, Prefilled; 0.55 ml
  • Hydralazine; 25mg; Tablet; 56 Tablets
  • Hydralazine; 25mg; Tablet; 84 Tablets
  • Hydrochlorothiazide; 12.5mg; Tablet; 28 Tablets
  • Hydrocortisone; 1%; Cream; 20 g
  • Hydrocortisone; 1%; Ointment; 25 g
  • Hydrocortisone; 10mg; Tablet; 100 Tablets
  • Hydroxypropylmethylcellulose; 3mg/ml; Drop, Eye; 20 ml
  • Hydroxyurea; 500mg; Capsule; 100 Capsules
  • Hyoscine butylbromide; 10mg; Tablet; 10 Tablets
  • Hyoscine butylbromide; 20mg/ml; injection; 1 ml
  • Hyoscine butylbromide; 5mg/5ml; Syrup; 100 ml
  • Ibandronic acid; 6mg; injection; 6 ml
  • Ibuprofen; 100mg/5ml; Suspension; 100 ml
  • Ibuprofen; 400mg; Tablet; 100 Tablets
  • Ibuprofen; 400mg; Tablet; 84 Tablets
  • Ifosfamide; 1g; injection; 1 Injection
  • Ifosfamide; 2g; injection; 1 Injection
  • Ifosfamide; 500mg; injection; 1 Injection
  • Imatinib; 100mg; Capsule; 60 Capsules
  • Imatinib; 400mg; Capsule; 30 Capsules
  • Imipenem, Cilastatin; 500mg, 500mg; injection; 1 Injection
  • Immunoglobulin, Anti-D; 100mcg; injection; 2 ml
  • Immunoglobulin, Hepatitis B; 100IU/2ml; injection; 1 Injection
  • Immunoglobulin, Human, Normal; 12g; Infusion (parenteral); 1 Injection
  • Immunoglobulin, Human, Normal; 16%; injection; 2 ml
  • Immunoglobulin, Human, Normal; 16%; injection; 5 ml
  • Immunoglobulin, Human, Normal; 1g; Infusion (parenteral); 1 Injection
  • Immunoglobulin, Human, Normal; 3g; Infusion (parenteral); 1 Injection
  • Immunoglobulin, Human, Normal; 6g; Infusion (parenteral); 1 Injection
  • Immunoglobulin, Rabies; 150IU/ml; injection; 2 ml
  • Indometacin; 25mg; Capsule; 100 Capsules
  • Insulin, Biosynthetic, Human, Isophane; 100IU/ml; injection; 10 ml
  • Insulin, Biosynthetic, Human, Isophane; 100IU/ml; pen, prefilled; 3 ml
  • Insulin, Biosynthetic, Human, Biphasic 30/70; 100IU/ml; injection; 10 ml
  • Insulin, Biosynthetic, Human, Biphasic 30/70; 100IU/ml; pen, prefilled; 3 ml
  • Insulin, Biosynthetic, Human, Soluble; 100IU/ml; injection; 10 ml
  • Insulin, Biosynthetic, Human, Soluble; 100IU/ml; pen, prefilled; 3 ml
  • Interferon Beta-1a; 6MIU; injection; 1 Injection
  • Interferon Beta-1b; 8MIU; injection; 1 Injection
  • Iohexol; 300mg/ml; injection; 100 ml
  • Iohexol; 300mg/ml; injection; 20 ml
  • Iohexol; 300mg/ml; injection; 50 ml
  • Iohexol; 350mg/ml; injection; 100 ml
  • Iohexol; 350mg/ml; injection; 50 ml
  • Iomeprol; 400mg/ml; injection; 100 ml
  • Iopamidol; 370mg/ml; injection; 100 ml
  • Iopamidol; 370mg/ml; injection; 50 ml
  • Iopromide; 300mg/ml; injection; 50 ml
  • Iopromide; 370mg/ml; injection; 100 ml
  • Ipratropium Bromide; 20mcg; Inhaler; 200 Doses
  • Ipratropium Bromide; 250mcg/2ml; solution, inhalation; 60 UDVs (2ml)
  • Ipratropium Bromide; 500mcg/2ml; solution, inhalation; 60 UDVs (2ml)
  • Irinotecan; 100mg/5ml; injection; 5 ml
  • Irinotecan; 40mg/2ml; injection; 2 ml
  • Iron (III) Hydroxide Dextran Complex; 100mg/2ml; injection; 2 ml
  • Iron (III) Hydroxide Dextran Complex; 500mg/10ml; injection; 10 ml
  • Iron Sucrose Co; 100mg/5ml; injection; 5 ml
  • Isoflurane; Liquid; 250 ml
  • Isosorbide Dinitrate; 10mg; Tablet; 84 Tablets
  • Isosorbide Dinitrate; 5mg; Tablet; 50 Tablets
  • Isosorbide mononitrate; 20mg; Tablet; 56 Tablets
  • IUD, Copper; Implant; 1 Device
  • IUD, Levonorgestrel; 52mg; Implant; 1 Device
  • Ketamine; 1000mg/10ml; injection; 10 ml
  • Ketamine; 200mg/20ml; injection; 20 ml
  • Ketamine; 500mg/10ml; injection; 10 ml
  • Ketoconazole; 200mg; Tablet; 30 Tablets
  • Lactulose; 3.35g/5ml; Syrup; 150 ml
  • Lactulose; 3.35g/5ml; Syrup; 500 ml
  • Lamotrigine; 100mg; Tablet; 56 Tablets
  • Lamotrigine; 200mg; Tablet; 56 Tablets
  • Lamotrigine; 25mg; Tablet; 56 Tablets
  • Lamotrigine; 50mg; Tablet; 56 Tablets
  • Lanolin; 3%; ointment, eye; 3.5 g
  • Leflunomide; 10mg; Tablet; 30 Tablets
  • Leflunomide; 20mg; Tablet; 30 Tablets
  • Letrozole; 2.5mg; Tablet; 28 Tablets
  • Levodopa, Carbidopa; 100mg, 25mg; Tablet; 100 Tablets
  • Levodopa, Carbidopa; 250mg, 25mg; Tablet; 100 Tablets
  • Levofloxacin; 250mg; Tablet; 28 Tablets
  • Levofloxacin; 500mg; Tablet; 28 Tablets
  • Levonorgestrel, Ethinylestradiol, Triphasic; Tablet; 28 Tablets
  • Levonorgestrel, Ethinylestradiol; 0.15mg, 0.03mg; Tablet (Monophasic); 28 Tablets
  • Levonorgestrel; 0.03mg; Tablet; 28 Tablets
  • Levonorgestrel; 1.5mg; Tablet; 1 Tablet
  • Levothyroxine Sodium; 100mcg; Tablet; 30 Tablets
  • Levothyroxine Sodium; 25mcg; Tablet; 28 Tablets
  • Levothyroxine Sodium; 50mcg; Tablet; 100 Tablets
  • Levothyroxine Sodium; 50mcg; Tablet; 30 Tablets
  • Lidocaine, Epinephrine (Adrenaline); 2%, 12.5mg; dental cartridge; 1.8 ml
  • Lidocaine; 1%; injection (not for iv use); 20 ml
  • Lidocaine; 10%; injection; 5 ml
  • Lidocaine; 2%; dental cartridge; 1.8 ml
  • Lidocaine; 2%; injection (not for iv use); 20 ml
  • Lidocaine; 2%; injection (not for iv use); 5 ml
  • Linezolid; 100mg/5ml; Suspension; 150 ml
  • Linezolid; 600mg/300ml; Infusion (parenteral); 300 ml
  • Linezolid; 600mg; Tablet; 10 Tablets
  • Liquid Paraffin; BP; Liquid; 200 ml
  • Lopinavir, Ritonavir; 100mg, 25mg; Tablet; 60 Tablets
  • Lopinavir, Ritonavir; 40mg, 10mg; Capsule; 120 Capsules
  • Lopinavir, Ritonavir; 80mg/ml, 20mg/ml; Solution; 60 ml
  • Lorazepam; 1mg; Tablet; 100 Tablets
  • Lorazepam; 2.5mg; Tablet; 100 Tablets
  • Losartan; 100mg; Tablet; 28 Tablets
  • Losartan; 50mg; Tablet; 30 Tablets
  • Lubricant, Jelly; Gel; 1 sachet (2.5g)
  • Lubricant, Jelly; Gel; 50 g
  • Lyophilised Plasma; Infusion (parenteral); 200 ml
  • Lyophilised Plasma; Infusion (parenteral); 50 ml
  • Magnesium Sulfate; 50%; injection; 2 ml
  • Mannitol; 25%; injection; 50 ml
  • Mannitol; 5%; Infusion (parenteral); 3 L
  • Mebendazole; 100mg/5ml; Suspension; 30 ml
  • Mebendazole; 100mg; Tablet; 6 Tablets
  • Mebendazole; 500mg; Tablet; 1 Tablet
  • Medroxyprogesterone; 10mg; Tablet; 30 Tablets
  • Medroxyprogesterone; 150mg; injection; 1 Injection
  • Medroxyprogesterone; 5mg; Tablet; 30 Tablets
  • Melphalan; 2mg; Tablet; 25 Tablets
  • Melphalan; 50mg; injection; 1 Injection
  • Mercaptopurine; 50mg; Tablet; 25 Tablets
  • Meropenem; 1g; injection; 30 ml
  • Meropenem; 500mg; injection; 20 ml
  • Mesalazine; 400mg; Tablet; 90 Tablets
  • Mesna; 400mg; injection; 1 Injection
  • Metformin; 500mg; Tablet; 112 Tablets
  • Methadone; 2mg; Solution; 60 ml
  • Methotrexate; 1g/10ml; injection; 10 ml
  • Methotrexate; 2.5mg; Tablet; 100 Tablets
  • Methotrexate; 50mg/2ml; injection; 2 ml
  • Methotrexate; 5g/50ml; injection; 50 ml
  • Methyl Salicylate; 10%; Ointment; 25 g
  • Methyl Salicylate; 10%; Ointment; 25 g
  • Methyldopa; 250mg; Tablet; 56 Tablets
  • Methyldopa; 250mg; Tablet; 84 Tablets
  • Methylphenidate; 10mg; Tablet; 30 Tablets
  • Methylprednisolone Acetate; 40mg/ml; injection; 2 ml
  • Methylprednisolone Acetate; 40mg/ml; injection; 5 ml
  • Methylprednisolone Sodium Succinate; 500mg/8ml; injection; 8 ml
  • Methylprednisolone; 40mg; injection; 1 Injection
  • Metoclopramide; 10mg/2ml; injection; 2 ml
  • Metoclopramide; 10mg; Tablet; 100 Tablets
  • Metoclopramide; 5mg/5ml; Syrup; 100 ml
  • Metronidazole; 200mg/5ml; Suspension; 100 ml
  • Metronidazole; 200mg; Tablet; 21 Tablets
  • Metronidazole; 200mg; Tablet; 21 Tablets
  • Metronidazole; 200mg; Tablet; 250 Tablets
  • Metronidazole; 200mg; Tablet; 28 Tablets
  • Metronidazole; 400mg; Tablet; 100 Tablets
  • Metronidazole; 400mg; Tablet; 21 Tablets
  • Micafungin; 100mg; injection; 1 Injection
  • Micafungin; 50mg; injection; 1 Injection
  • Miconazole; 2%; Gel, Oral; 30 g
  • Midazolam; 15mg; Tablet; 20 Tablets
  • Midazolam; 50mg/10ml; injection; 10 ml
  • Midazolam; 7.5mg; Tablet; 20 Tablets
  • Mifepristone; 200mg; Tablet; 3 Tablets
  • Minoxidil; 10mg; Tablet; 100 Tablets
  • Minoxidil; 5mg; Tablet; 100 Tablets
  • Misoprostol; 200mcg; Tablet; 60 Tablets
  • Montelukast; 10mg; Tablet; 30 Tablets
  • Montelukast; 4mg; Tablet, chew; 30 Tablets
  • Montelukast; 5mg; Tablet; 30 Tablets
  • Morphine; BP; Powder; 10 g
  • Morphine; 10mg; Tablet, MR; 60 Tablets
  • Morphine; 30mg; Tablet, MR; 60 Tablets
  • Morphine; 60mg; Tablet, MR; 60 Tablets
  • Moxifloxacin; 400mg/250ml; injection; 250 ml
  • Moxifloxacin; 400mg; Tablet; 10 Tablets
  • Moxifloxacin; 400mg; Tablet; 28 Tablets
  • Moxifloxacin; 400mg; Tablet; 5 Tablets
  • Multichamber TPN for Adults: High volume bag with electrolytes, Very high protein, Very high calorie for central line; Infusion (parenteral); 2 L
  • Multichamber TPN for Adults: High volume bag with electrolytes: high protein, very high calorie for central line; Infusion (parenteral); 2 L
  • Multichamber TPN for Adults: High volume bag with electrolytes: Moderate protein, high calorie through central line; Infusion (parenteral); 2 L
  • Multichamber TPN for Adults: Low volume bag with electrolytes: low protein, moderate calorie through central line; Infusion (parenteral); 1.5 L
  • Multichamber TPN for Adults: Moderate volume bag with electrolytes: Moderate protein, high calorie through central line; Infusion (parenteral); 1.5 L
  • Multichamber TPN for Adults: Moderate volume bag without electrolytes: Moderate protein, high calorie through central line; Infusion (parenteral); 1 L
  • Multichamber TPN for Adults: Very low volume weaning bag with electrolytes: very low protein, low calorie for central line; Infusion (parenteral); 1 L
  • Mycophenolate Mofetil; 200mg/ml; Suspension; 175 ml
  • Mycophenolate Mofetil; 250mg; Capsule; 100 Capsules
  • Mycophenolate Mofetil; 500mg; Tablet; 50 Tablets
  • Mycophenolic Acid; 180mg; Tablet; 120 Tablets
  • Mycophenolic Acid; 360mg; Tablet; 120 Tablets
  • Naloxone; 400mcg/ml; injection; 1 ml
  • Naloxone; 40mcg/2ml; injection; 2 ml
  • Neonatal Maintenance, Dextrose (Potassium Free); 33,5,33,100mmol; Infusion (parenteral); 200 ml
  • Neonatal Maintenance, Dextrose; 20,15,2.5,0.5,21,2mmol, 10%; Infusion (parenteral); 200 ml
  • Neostigmine; 2.5mg/ml; injection; 1 ml
  • Nevirapine; 200mg; Tablet; 56 Tablets
  • Nevirapine; 50mg/5ml; Suspension; 100 ml
  • Nevirapine; 50mg/5ml; Suspension; 240 ml
  • Nifedipine; 10mg; Capsule; 100 Capsules
  • Nifedipine; 5mg; Capsule; 100 Capsules
  • Nilotinib; 150mg; Capsule; 112 Capsules
  • Nilotinib; 200mg; Capsule; 112 Capsules
  • Nitrofurantoin; 100mg; Capsule; 50 Capsules
  • Norethisterone Acetate; 5mg; Tablet; 30 Tablets
  • Norethisterone Enanthate; 200mg/ml; injection; 1 ml
  • Norgestrel, Ethinylestradiol; 0.5mg, 0.05mg; Tablet; 28 Tablets
  • Nystatin; 100000IU/ml; Drop, Oral; 20 ml
  • Octreotide; 0.05mg/ml; injection; 1 Injection
  • Octreotide; 0.1mg/ml; injection; 1 Injection
  • Olanzapine; 10mg; Tablet; 28 Tablets
  • Olanzapine; 2.5mg; Tablet; 28 Tablets
  • Olanzapine; 5mg; Tablet; 28 Tablets
  • Olopatadine; 1mg/ml; Drop, Eye; 5 ml
  • Ondansetron; 4mg/2ml; injection; 2 ml
  • Ondansetron; 4mg; Tablet, dispersible; 10 Tablets
  • Ondansetron; 8mg/4ml; injection; 4 ml
  • Ondansetron; 8mg; Tablet; 10 Tablets
  • Oral Rehydration; Powder; 1 Sachet
  • Orphenadrine; 50mg; Tablet; 28 Tablets
  • Orphenadrine; 50mg; Tablet; 56 Tablets
  • Orphenadrine; 50mg; Tablet; 84 Tablets
  • Oxaliplatin; 100mg; injection; 1 Injection
  • Oxaliplatin; 50mg; injection; 1 Injection
  • Oxazepam; 10mg; Tablet; 100 Tablets
  • Oxazepam; 30mg; Tablet; 100 Tablets
  • Oxybuprocaine; 0.4%; Drop, Eye; 3 ml
  • Oxybutynin; 5mg; Tablet; 84 Tablets
  • Oxymetazoline; 0.025%; Drop, Eye; 15 ml
  • Oxymetazoline; 0.025%; Drop, Nasal; 10 ml
  • Oxymetazoline; 0.05%; Drop, Nasal; 10 ml
  • Oxymetazoline; 0.05%; Spray, Nasal; 15 ml
  • Oxytocin; 5IU/ml; injection; 1 ml
  • Paclitaxel; 100mg/16.7ml; injection; 16.7 ml
  • Paclitaxel; 30mg/5ml; injection; 5 ml
  • Pancreatin: Lipase, Amylase, Protease; 150mg; Capsule; 100 Capsules
  • Pancreatin: Lipase, Amylase, Protease; 300mg; Capsule; 100 Capsules
  • Pantoprazole; 40mg; injection; 1 Injection
  • Paracetamol; 120mg/5ml; Syrup; 100 ml
  • Paracetamol; 120mg/5ml; Syrup; 50 ml
  • Paracetamol; 120mg/5ml; Syrup; 500 ml
  • Pethidine; 25mg/ml; injection; 1 ml
  • Phenobarbital, Vitamin B3 (Nicotinamide), Vitamin B6 (Pyridoxine), Vitamin B2 (Riboflavin), Vitamin B1 (Thiamine); 16mg/5ml, 10mg/5ml, 0.25mg/5ml, 1mg/5ml, 3mg/5ml; Syrup; 100 ml
  • Phenobarbital; 30mg; Tablet; 28 Tablets
  • Phenobarbital; 30mg; Tablet; 56 Tablets
  • Phenobarbital; 30mg; Tablet; 84 Tablets
  • Phenoxymethylpenicillin; 125mg/5ml; Suspension; 100 ml
  • Phenoxymethylpenicillin; 250mg/5ml; Suspension; 100 ml
  • Phenoxymethylpenicillin; 250mg; Tablet; 100 Tablets
  • Phenoxymethylpenicillin; 250mg; Tablet; 40 Tablets
  • Phenylephrine; 10mg/ml; injection; 1 ml
  • Phenytoin; 100mg; Capsule; 100 Capsules
  • Phenytoin; 100mg; Capsule; 84 Capsules
  • Phenytoin; 250mg/5ml; injection; 5 ml
  • Phospholipids, Total; 100mg/4ml; injection; 4 ml
  • Phospholipids, Total; 200mg/8ml; injection; 8 ml
  • Pilocarpine; 1%; Drop, Eye; 15 ml
  • Piperacillin, Tazobactam; 4g, 500mg; injection; 30 ml
  • Polystyrene Sulfonate; Powder; 454 g
  • Potassium Chloride; BP; Powder; 500 g
  • Potassium Chloride; 15%; injection; 10 ml
  • Potassium Chloride; 600mg; Tablet; 100 Tablets
  • Potassium Citrate; BP; Suspension; 200 ml
  • Povidone Iodine; 1%; Liquid; 100 ml
  • Povidone Iodine; 10%; Liquid; 1 L
  • Povidone Iodine; 10%; Ointment; 25 g
  • Povidone Iodine; 10%; Ointment; 500 g
  • Povidone Iodine; 5%; Cream; 25 g
  • Povidone Iodine; 5%; Cream; 500 g
  • Pramipexole; 0.125mg; Tablet; 100 Tablets
  • Pramipexole; 0.25mg; Tablet; 100 Tablets
  • Pramipexole; 1mg; Tablet; 100 Tablets
  • Praziquantel; 500mg; Tablet; 100 Tablets
  • Prednisolone; 1%; Drop, Eye; 5 ml
  • Prednisone; 5mg; Tablet; 100 Tablets
  • Prednisone; 5mg; Tablet; 40 Tablets
  • Prednisone; 5mg; Tablet; 56 Tablets
  • Promethazine; 25mg/ml; injection; 1 ml
  • Promethazine; 25mg; Tablet; 100 Tablets
  • Promethazine; 50mg/2ml; injection; 2 ml
  • Promethazine; 5mg/5ml; Elixir; 100 ml
  • Propofol; 10mg/ml; injection; 20 ml
  • Propofol; 10mg/ml; injection; 50 ml
  • Propranolol; 10mg; Tablet; 250 Tablets
  • Propranolol; 10mg; Tablet; 28 Tablets
  • Propranolol; 10mg; Tablet; 50 Tablets
  • Propranolol; 10mg; Tablet; 84 Tablets
  • Propranolol; 40mg; Tablet; 250 Tablets
  • Propranolol; 40mg; Tablet; 56 Tablets
  • Propranolol; 40mg; Tablet; 84 Tablets
  • Propylene Glycol; BP; Liquid; 2.5 L
  • Pyrazinamide; 500mg; Tablet; 28 Tablets
  • Pyrazinamide; 500mg; Tablet; 56 Tablets
  • Pyrazinamide; 500mg; Tablet; 84 Tablets
  • Pyridostigmine; 10mg; Tablet; 50 Tablets
  • Pyridostigmine; 60mg; Tablet; 150 Tablets
  • Quetiapine; 100mg; Tablet; 90 Tablets
  • Quetiapine; 200mg; Tablet; 60 Tablets
  • Quetiapine; 25mg; Tablet; 100 Tablets
  • Quetiapine; 300mg; Tablet; 60 Tablets
  • Quinine; 300mg/ml; injection; 1 ml
  • Raltegravir; 100mg; Tablet; 56 Tablets
  • Raltegravir; 25mg; Tablet; 56 Tablets
  • Raltegravir; 400mg; Tablet; 56 Tablets
  • Ranitidine; 50mg/2ml; injection; 2 ml
  • Recombinant Anthihaemophilic Factor VIII; 1000IU; injection; 1 Dose
  • Recombinant Anthihaemophilic Factor VIII; 250IU; injection; 1 Dose
  • Recombinant Anthihaemophilic Factor VIII; 500IU; injection; 1 Dose
  • Rifampicin, Isoniazid; 60mg, 60mg; Tablet; 28 Tablets
  • Rifampicin, Isoniazid; 60mg, 60mg; Tablet; 56 Tablets
  • Rifampicin, Isoniazid; 75mg, 50mg; Tablet; 84 Tablets
  • Rifampicin, Pyrazinamide, Ethambutol, Isoniazid; 150mg, 400mg, 275mg, 75mg; Tablet; 28 Tablets
  • Rifampicin, Pyrazinamide, Isoniazid; 75mg, 150mg, 50mg; Tablet; 84 Tablets
  • Rifampicin; 150mg; Capsule; 100 Capsules
  • Rifapentine; 150mg; Tablet; 24 Tablets
  • Ringer Lactate; Infusion (parenteral); 1 L
  • Ringer Lactate; Infusion (parenteral); 200 ml
  • Risedronic Acid; 35mg; Tablet; 4 Tablets
  • Risperidone; 0.5mg; Tablet; 30 Tablets
  • Risperidone; 1mg/ml; Solution; 30 ml
  • Risperidone; 1mg; Tablet; 30 Tablets
  • Risperidone; 2mg; Tablet; 30 Tablets
  • Risperidone; 3mg; Tablet; 30 Tablets
  • Ritonavir; 100mg; Suspension; 30 Sachets
  • Ritonavir; 100mg; Tablet; 56 Tablets
  • Rituximab; 100mg/10ml; injection; 10 ml
  • Rituximab; 500mg/50ml; injection; 50 ml
  • Rocuronium Bromide; 50mg/5ml; injection; 5 ml
  • Rosuvastatin; 10mg; Tablet; 30 Tablets
  • Salbutamol, Ipratropium Bromide; 2.5mg/2.5ml, 0.5mg/2.5ml; solution, inhalation; 60 UDVs (2.5ml)
  • Salmeterol, Fluticasone; 25mcg, 250mcg; Inhaler; 120 Doses
  • Salmeterol, Fluticasone; 25mcg, 50mcg; Inhaler; 120 Doses
  • Selenium Sulfide; 2.5%; Suspension; 50 ml
  • Senna Glycosides; 13.5mg; Tablet; 20 Tablets
  • Sevoflurane; BP; Liquid; 250 ml
  • Silver Sulfadiazine; 1%; Cream; 250 g
  • Silver Sulfadiazine; 1%; Cream; 50 g
  • Silver Sulfadiazine; 1%; Cream; 500 g
  • Sirolimus; 1mg; Tablet; 30 Tablets
  • Sodium Bicarbonate; 4%; injection; 50 ml
  • Sodium Bicarbonate; 4.2%; Infusion (parenteral); 200 ml
  • Sodium Bicarbonate; 8.5%; injection; 50 ml
  • Sodium Chloride, Dextrose; 0.2%, 5%; Infusion (parenteral); 200 ml
  • Sodium Chloride, Dextrose; 0.45%, 5%; Infusion (parenteral); 1 L
  • Sodium Chloride, Dextrose; 0.9%, 5%; Infusion (parenteral); 1 L
  • Sodium Chloride, Dextrose; 0.9%, 5%; Infusion (parenteral); 200 ml
  • Sodium Chloride; BP; Powder; 500 g
  • Sodium Chloride; 0.45%; Infusion (parenteral); 1 L
  • Sodium Chloride; 0.9%; Infusion (parenteral); 1 L
  • Sodium Chloride; 0.9%; Infusion (parenteral); 100 ml
  • Sodium Chloride; 0.9%; Infusion (parenteral); 200 ml
  • Sodium Chloride; 0.9%; Infusion (parenteral); 200 ml
  • Sodium Chloride; 0.9%; Infusion (parenteral); 50 ml
  • Sodium Chloride; 0.9%; solution, irrigation, bag; 1 L
  • Sodium Chloride; 0.9%; solution, irrigation, bag; 3 L
  • Sodium Chloride; 0.9%; solution, irrigation, bottle; 1 L
  • Sodium Chloride; 0.9%; solution, irrigation; 30 ml
  • Sodium Chloride; 5%; Infusion (parenteral); 200 ml
  • Sodium Phosphate, Sodium Acid Phosphate; Enema; 135 ml
  • Sodium, Potassium, Calcium, Lactate; 131mmol, 5mmol, 108mmol, 29mmol; Infusion (parenteral) (Plasmalyte L); 1 L
  • Sodium, Potassium, Calcium, Lactate; 35mmol/L, 12mmol/L, 47mmol/L, 50g/L; Infusion (parenteral) (Paediatric Maintenance); 500 ml
  • Sodium, Potassium, Calcium, Lactate; 35mmol/L, 12mmol/L, 47mmol/L, 50g/L; Infusion (parenteral) (Paediatric Maintenance); 200 ml
  • Soft Paraffin, White; BP; Ointment; 500 g
  • Somatropin; 10mg/1.5ml; cartridge; 1.5 ml
  • Somatropin; 5mg/1.5ml; cartridge; 1.5 ml
  • Sorbitol; 70%; Solution; 500 ml
  • Spacer With Mask For Adults; Medical device; 1 Device
  • Spacer With Mask For Children; Medical device; 1 Device
  • Spacer With Mask For Infants; Medical device; 1 Device
  • Spironolactone; 100mg; Tablet; 60 Tablets
  • Spironolactone; 25mg; Tablet; 200 Tablets
  • Spironolactone; 25mg; Tablet; 56 Tablets
  • Spironolactone; 25mg; Tablet; 84 Tablets
  • Streptokinase; 1.5MIU; injection; 1 Injection
  • Sulfamethoxazole, Trimethoprim; 400mg, 80mg; Tablet (Co-trimoxazole); 100 Tablets
  • Sulfamethoxazole, Trimethoprim; 400mg/5ml, 80mg/5ml; injection; 5 ml
  • Sulfasalazine; 500mg; Tablet; 100 Tablets
  • Sunscreen; 30SPF; Cream; 150 ml
  • Suxamethonium; 100mg/2ml; injection; 2 ml
  • Syrup, Simplex; BP; Syrup; 2.5 L
  • Tacrolimus; 0.5mg; Capsule; 30 Capsules
  • Tacrolimus; 1mg; Capsule; 30 Capsules
  • Tacrolimus; 5mg; Capsule; 30 Capsules
  • Tamoxifen; 20mg; Tablet; 28 Tablets
  • Tenofovir; 300mg; Tablet; 28 Tablets
  • Teriflunomide; 14mg; Tablet; 28 Tablets
  • Terizidone; 250mg; Capsule; 100 Capsules
  • Test: Blood Glucose; test strip; 50 Test Strips
  • Test: TB LAM AG; test kit; 25 Test Strips
  • Test: Urine, Gluc., Prot., Bl., pH, Ket., Leuc., Nit., Bilir., Urob.; test kit; 100 Test Strips
  • Tetracaine, Arnica, Salvia, Aluminium; Ointment; 10 g
  • Thalidomide; 50mg; Capsule; 28 Capsules
  • Theophylline; 200mg; Tablet, MR; 60 Tablets
  • Theophylline; 300mg; Tablet, MR; 60 Tablets
  • Timolol, Bimatoprost; 5mg/ml, 0.3mg/ml; Drop, Eye; 3 ml
  • Timolol, Brimonidine; 5mg/ml, 2mg/ml; Drop, Eye; 5 ml
  • Timolol, Travoprost; 5mg/ml, 40mcg/ml; Drop, Eye; 2.5 ml
  • Tioguanine; 40mg; Tablet; 25 Tablets
  • Topiramate; 100mg; Tablet; 60 Tablets
  • Topiramate; 15mg; Capsule, Sprinkle; 60 Capsules
  • Topiramate; 25mg; Tablet; 60 Tablets
  • Topiramate; 50mg; Tablet; 60 Tablets
  • TPN for Adults: High volume bag with electrolytes: high protein, high calorie for central line; Infusion (parenteral); 2 L
  • TPN for Adults: Moderate volume bag without electrolytes: Moderate protein, high calorie For IV infusion through central line. Multichamber bag containing: Amino Acids: a minimum of histidine,
  • TPN for Adults: Very low volume weaning bag with electrolytes: very low protein, low calorie for peripheral line; Infusion (parenteral); 1 L
  • Trace Elements; injection; 10 ml
  • Tramadol; 100mg/2ml; injection; 2 ml
  • Tramadol; 100mg; Tablet, MR; 60 Tablets
  • Tranexamic Acid; 500mg/5ml; injection; 5 ml
  • Tranexamic Acid; 500mg; Tablet; 30 Tablets
  • Trastuzumab; 440mg; injection; 1 Injection
  • Tretinoin; 0.025%; Gel; 20 g
  • Tretinoin; 10mg; Capsule; 100 Capsules
  • Tropicamide; 1%; Drop, Eye; 15 ml
  • Vaccine: BCG; Injection; 20 Doses
  • Vaccine: Diphtheria, Tetanus; 2IU/20IU; injection; 10 Doses
  • Vaccine: Diptheria, Haemophilus Influenzae B, Pertussis, Polio, Tetanus, Hepatitis B; Syringe, Prefilled; 1 Dose
  • Vaccine: Hepatitis B Adult; 20mcg/ml; injection; 1 Dose
  • Vaccine: Hepatitis B Peadiatric; 10mcg/0.5ml; injection; 10 Doses
  • Vaccine: Human Papillomavirus, Bivalent; injection; 2 Doses
  • Vaccine: Influenza; Syringe, Prefilled; 1 Dose
  • Vaccine: Measles; injection; 10 Doses
  • Vaccine: Meningococcal Polysaccharide Diphtheria Toxoid Conjugate; injection; 1 Dose
  • Vaccine: Pneumococcal, 23-Valent Polysaccharide; injection; 1 Dose
  • Vaccine: Pneumococcal, Conjugated; Syringe, Prefilled; 1 Dose
  • Vaccine: Rabies; injection; 1 Dose
  • Vaccine: Rotavirus; Drop, Oral; 1 Dose
  • Vaccine: Tetanus Toxoid; injection; 10 Doses
  • Vaccine: Yellow Fever; injection; 1 Dose
  • Valganciclovir; 450mg; Tablet; 60 Tablets
  • Valproate Sodium; 100mg; Tablet, dispersible; 100 Tablets
  • Valproic Acid, Valproate Sodium; 145mg, 333mg; Tablet, MR; 100 Tablets
  • Valproic Acid, Valproate Sodium; 145mg, 333mg; Tablet, MR; 56 Tablets
  • Valproic Acid, Valproate Sodium; 58mg, 133.2mg; Tablet, MR; 100 Tablets
  • Valproic Acid, Valproate Sodium; 58mg, 133.2mg; Tablet, MR; 56 Tablets
  • Valproic Acid, Valproate Sodium; 87mg, 199.8mg; Tablet, MR; 100 Tablets
  • Valproic Acid, Valproate Sodium; 87mg, 199.8mg; Tablet, MR; 56 Tablets
  • Valproic Acid; 200mg/5ml; Syrup; 300 ml
  • Valproic Acid; 250mg/5ml; Syrup; 100 ml
  • Vancomycin; 1g; injection; 1 Injection
  • Vancomycin; 500mg; injection; 1 Injection
  • Vecuronium; 4mg/2ml; injection; 2 ml
  • Venlafaxine; 150mg; Tablet, MR; 30 Tablets
  • Venlafaxine; 37.5mg; Tablet; 30 Tablets
  • Venlafaxine; 75mg; Tablet; 30 Tablets
  • Verapamil; 240mg; Tablet, MR; 30 Tablets
  • Verapamil; 40mg; Tablet; 84 Tablets
  • Vinblastine; 10mg/10ml; injection; 1 Injection
  • Vincristine; 2mg/2ml; injection; 2 ml
  • Vitamin A (Retinol); 100,000IU; Capsule; 50 Capsules
  • Vitamin A (Retinol); 200,000IU; Capsule; 50 Capsules
  • Vitamin A (Retinol); 50,000IU; Capsule; 50 Capsules
  • Vitamin B1 (Thiamine); 100mg/ml; injection; 10 ml
  • Vitamin B1 (Thiamine); 100mg; Tablet; 84 Tablets
  • Vitamin B12 (Cyanocobalamin); 1mg/ml; injection; 1 ml
  • Vitamin B3 (Nicotinamide); 100mg; Tablet; 28 Tablets
  • Vitamin B3 (Nicotinamide); 100mg; Tablet; 84 Tablets
  • Vitamin B6 (Pyridoxine); 25mg; Tablet; 100 Tablets
  • Vitamin D (Alfacalcidol); 0.25mcg; Capsule; 30 Capsules
  • Vitamin D (Alfacalcidol); 1mcg; Capsule; 30 Capsules
  • Vitamin D2 (Ergocalciferol); 5,000IU/ml; Drop, Oral; 15 ml
  • Vitamin D2 (Ergocalciferol); 50,000IU; Tablet; 100 Tablets
  • Vitamin D3 (Calcitriol); 0.25mcg; Capsule; 30 Capsules
  • Vitamin K1 (Phytomenadione); 10mg; injection; 1 ml
  • Vitamin K1 (Phytomenadione); 2mg; injection; 0.2 ml
  • Vitamin, Fat Soluble, Vitamin E; injection; 10 ml
  • Vitamin, Multi; Drop, Oral; 25 ml
  • Vitamin, Multi; injection; 10 ml
  • Vitamin, Multi; Syrup; 100 ml
  • Vitamin, Water Soluble; injection (for intravenous use in adults); 10 ml
  • Warfarin; 5mg; Tablet; 100 Tablets
  • Water For Injection; injection; 10 ml
  • Water For Injection; injection; 20 ml
  • Water For Irrigation; Liquid (Pour Water); 1 L
  • Water For Irrigation; Liquid; 1 L
  • Water For Irrigation; Liquid; 3 L
  • Zidovudine, Lamivudine; 300mg, 150mg; Tablet; 56 Tablets
  • Zidovudine, Lamivudine; 300mg, 150mg; Tablet; 56 Tablets
  • Zidovudine; 100mg; Capsule; 100 Capsules
  • Zidovudine; 300mg; Capsule; 56 Capsules
  • Zidovudine; 50mg/5ml; Syrup; 200 ml
  • Zinc Oxide, Castor Oil; Ointment; 25 g
  • Zinc Sulfate; 10mg/5ml; Syrup; 150 ml
  • Zinc Sulfate; 20mg; Tablet; 10 Tablets
  • Zinc Sulfate; 20mg; Tablet; 100 Tablets
  • Zuclopentixol Acetate; 50mg/ml; injection; 1 ml
  • Zuclopentixol Decanoate; 200mg/ml; injection; 1 ml

END.

11 April 2023 - NW932

Profile picture: Seitlholo, Mr IS

Seitlholo, Mr IS to ask the Minister of Health

(1)Whether the interim council has been appointed, following the notice on 31 January 2022 published in the Government Gazette 45845 for submission for nomination regarding the Traditional Health Practitioners Council and the appointment of the interim members of the specified council; if not, why not; if so, 2) whether section 6 of the Regulation Relating to the Appointment of Members of the Interim Traditional Health Practitioners Council of South Africa, Act 22 of 2007, was complied with; if not, why not; if so, what are the relevant details; (3) whether the council has complied with the expected functions in terms of the Traditional Health Practitioners Act, Act 22 of 2007, and specifically relevant sections of the specified Act; if not, why not; if so, what are the relevant details; (4) whether the council has (a) telephone numbers, (b) an email address and (c) offices from which registration of traditional health practitioners can be verified and authenticated by the general public; if not, why not; if so, what are the relevant details?

Reply:

1. The Interim Traditional Health Practitioners Council of South Africa (ITHPCSA/Council) has not been appointed. The appointment of the ITHPCSA was pending consultation between the Minister and the traditional health practitioners’ stakeholders. The consultation in this regard was held on 23-24 February 2023.

2. Regulation 6 of the Regulations relating to the appointment of members of the ITHPCSA provides that the Minister must publish the names of persons appointed to the Council in the Gazette. This regulation will be complied with upon finalization of the appointment of Members of the Council.

3. The Council once appointed will be expected to comply with the provisions of the Traditional Health Practitioners Act, 2007 (Act No. 22 of 2007).

4. The process to register traditional health practitioners will be undertaken subsequent to the appointment of the Council. Enquiries related to the registration and other matters can be directed to the Interim Registrar: Mr Kgereshi Mokwena as follows: (012) 3958018; (b) [email protected] (c) Dr AB Xuma Building, 1112 Voortrekker Rd, Pretoria Townlands 351-JR, Pretoria

END.

11 April 2023 - NW892

Profile picture: Clarke, Ms M

Clarke, Ms M to ask the Minister of Health

(1)What (a) total number of (i) nurses, (ii) operational staff and (iii) clinicians have been absent at each State hospital in each province since 1 January 2021 and (b) were the reasons for the absence; (2) what (a) number of disciplinary cases have taken place due to the specified absences and (b) consequence management provisions have been put in place to deal with high absenteeism within the public health sector of the Republic?

Reply:

1. Leave of absence in the Public Service is regulated in accordance with the Directive on Leave of Absence as published by the Department of Public Service and Administration in August 2021.

In accordance with the information as extracted from the PERSAL data set-

a) (i) The data as provided gives overall number of days counts that Nurses (in all categories as employed in the Public Health Sector) took in different leave categories during the financial years 2021/2022 and 2002/2023 is as per the table below:

The tables below provide a breakdown of the various categories of absenteeism per provinces.

NUMBER OF DAYS ABSENT BY NURSES (IN ALL CATEGORIES)

 

EC

FS

GAU

KZN

LP

MPU

NW

NC

WC

Overall Total

Adoption (Workdays)

2

44

0

4

6

0

0

0

0

56

Discounting (Workdays)

102

1964

102

791

238

148

136

33

852

4366

Family Responsibility (Workdays)

7403

1542

2147

20103

14428

3755

2776

384

11203

63741

Gratuity (Workdays)

239

131

34

713

531

199

82

26

265

2220

Leave Without Pay (Calendar Days)

1540

269

359

3409

595

291

183

130

1421

8197

Maternity

576

163

217

1290

742

362

184

22

524

4080

Occupational Injuries/Diseases (Workdays)

185

41

67

833

1735

988

151

9

158

4167

Paternity (Workdays)

54

12

16

105

100

27

24

1

48

387

Permanent Incapacity Leave

7

1

121

13

598

3

155

9

7

914

Pre-Natal (Workdays)

308

161

154

1376

350

194

77

13

861

3494

Shop Steward/Office Bearer (Workdays)

663

183

87

1024

1052

258

183

78

595

4123

Sick-Full Pay (Workdays)

53276

19217

11953

145227

57858

17671

14473

2504

59599

381778

Special (Workdays)

1893

536

459

10173

3249

601

778

104

10795

28588

Temporary Incapacity Leave

1011

773

583

3358

872

431

343

37

1507

8915

Vacation - Full Pay (Workdays)

103013

37979

17654

214258

91977

38302

25891

4459

75251

608784

(ii) The Public Health Services does not make provision for a Job title of Operational Staff. It is requested that clear indication be provided on what is the meaning of Operational Staff.

(iii) The data as provided gives overall number of days counted that Clinicians (Medical Officers/ Specialist and Registrar’s) took in different leave categories during the financial years 2021/2022 and 2002/2023 is as per the table below.

The tables below provide a breakdown of the various categories of absenteeism per provinces.

NUMBER OF DAYS ABSENT BY CLINITIANS MEDICAL OFFICER / SPECIALIST / REGISTRARS

 

EC

FS

GAU

KZN

LP

MPU

NW

NC

WC

Overall Total

Adoption (Workdays)

1

0

0

0

0

2

0

0

1

4

Discounting (Workdays)

14

49

35

206

157

36

69

5

317

888

Family Responsibility (Workdays)

265

174

146

1491

906

284

146

37

726

4175

Gratuity (Workdays)

17

1

0

19

19

10

2

0

16

84

Leave Without Pay (Calendar Days)

20

19

38

261

262

29

18

0

163

810

Maternity

58

40

51

239

161

78

46

3

158

834

Occupational Injuries/Diseases (Workdays)

13

2

16

99

173

107

12

0

11

433

Paternity (Workdays)

20

17

14

99

77

20

15

5

74

341

Permanent Incapacity Leave

0

0

0

0

0

0

0

0

1

1

Pre-Natal (Workdays)

51

15

27

407

118

28

15

1

112

774

Shop Steward/Office Bearer (Workdays)

3

0

2

17

37

15

0

0

118

192

Sick-Full Pay (Workdays)

2011

962

1293

17565

4604

1862

928

184

6852

36261

Special (Workdays)

572

801

263

3440

1328

409

226

33

4505

11577

Temporary Incapacity Leave

19

33

16

140

18

9

10

2

95

342

Vacation - Full Pay (Workdays)

7990

5993

4328

34780

13685

6903

4198

651

23370

101898

2. The National Department of Health is consulting with the Provincial Departments of Health to collate the full details in this regard.

END.

11 April 2023 - NW1009

Profile picture: Tambo, Mr S

Tambo, Mr S to ask the Minister of Health

With reference to the rolling electricity black-outs that have had an adverse impact on the healthcare sector as well as reports that some healthand care facilities are impacted causing untold harm to patients, what (a) total number of (i) hospitals, (ii) clinics and (iii) healthcare facilities in the public sector are impacted by load shedding and (b) are the (i) names and (ii) locations of the affected facilities?

Reply:

(a)-(b) All health facilities have been affected by the load-shedding across the country and some core services, especially surgical interventions often have to be rescheduled. Fortunately, all hospitals have two back-up suppliers (e.g. generators and Uninterrupted Power Suppliers for theatres and ICU’s) and most of the Community Health Centres have one back-up supplier (e.g. generators). These back-up suppliers have assisted in reducing the impact of load-shedding and preventing untold harm to the patients. All health facilities are continuously adapting to ensure that they function optimally.

END.

11 April 2023 - NW879

Profile picture: Van Staden, Mr PA

Van Staden, Mr PA to ask the Minister of Health

(1)Whether, with reference to his reply to question 7 on 22 February 2023, he will indicate (a) what the proposed solar energy roll-out programme will involve, (b) by what date the specified programme will be rolled out and (c) what the envisaged completion date is; if not, why not, in each case; if so, what are the relevant details in each case; (2) whether he will make a statement on the matter?

Reply:

(1) My Department has appointed CSIR to conduct a due diligence exercise regarding the roll-out of solar energy to all health facilities across the country. (a) The proposed solar energy programme is going to cover the roll-out of the solar energy + battery storage as back-up supply to all the clinics, CHC’s, hospitals, EMS centres including the forensic laboratories. The objective of the exercise by CSIR is to identify the required critical consumption for critical areas of each health facility so that the department can be able:

- To compile a comprehensive business case that will assist the Department in justifying for the required budget;

- To identify critical areas within a “health facility” that requires a back-up service from the solar energy. CSIR is going to quantify the required size of solar energy for those critical areas;

- CSIR is going to consider different kits of inverters with batteries for the Clinics and CHC’s. Unlike solar panels, these kits are not easy to steal. They can be stored in a lockable room with burglar bars and with strict access control;

- To map out the roll-out implementation program for the required solar energy solution for each health facility;

- The study will also identify areas that can be funded by other donors like USAID including others that are interested to partner with the National Department of Health; and

- The exercise/study is expected to be completed at the end of April 2023.

(b) The expected start date of the roll-out of the solar energy programme is June 2023 depending on the availability of funding from the National State of Disaster Centre.

(c) The envisage completion date is going to be informed by the detailed analysis by CSIR.

(2) No.

END.

11 April 2023 - NW891

Profile picture: Clarke, Ms M

Clarke, Ms M to ask the Minister of Health

(a) What total number of (i) doctors, (ii) nurses and (iii) medical specialist personnel have been trained in the Republic and (b) of the specified number, what total number has been absorbed into the public healthcare sector since 1 January 2013?

Reply:

a) The total number of-

(i) As per the HPCSA register, a total of 16 964 doctors have been trained in the Republic since 01 January 2013.

(ii) As per the SA Nursing Council register, a total of 181 277 Nurses (all categories) have been trained in the Republic since 1 January 2013.

(iii) A total of 5 877 specialists have registered with the Health Professions Council of South Africa (HPCSA) after training in different fields of Specialty in the Republic since 1 January 2013.

b) Of the above trained numbers, the following have been absorbed in the Public Health Sector

(i) Doctors appointed since January 2013 in Public Health Sector is 15 606,

(ii) Nurses (all categories) appointed since January 2013 in Public Health Sector is 52 542 and

(iii) Medical Specialist appointed since January 2013 in the Public Health Sector is 4 293.

 

END.

11 April 2023 - NW854

Profile picture: Tito, Ms LF

Tito, Ms LF to ask the Minister of Health

Whether he has been informed that no ambulances nor mobile clinics are available to assist the community in Warmsand in the Northern Cape, whenever they are in need of healthcare and that residents have to travel to Upington in order to get assistance; if not, what is the position in this regard; if so, what are the relevant details?

Reply:

Yes, I have been informed that Warmsand in the Northern Cape is a farmstead located approximately 20 kilometres from Keimoes and is therefore serviced from Keimoes when required. Patients from all surrounding areas including Eenduin, Friersdale and Warmsand are being served from Keimoes and not Upington as mentioned in the report. There is an Emergency Medical Services (EMS) station in Keimoes that services Warmsand area.

Due to shortage of staff, the service regressed because of the national measles campaign conducted throughout the province. The mobile clinic with the support from Keimoes Community Health Centre (CHC) staff will resume the services with effect from the 1st week of April 2023 in Warmsand and the surrounding areas.

END.

11 April 2023 - NW860

Profile picture: Chirwa, Ms NN

Chirwa, Ms NN to ask the Minister of Health

(1)Whether, considering the historical concerns with regard to the influence of Mr Bill Gates over the South African healthcare system, with specific reference to the vaccine programmes during COVID-19 and the funding of the SA Health Products Regulatory Authority, he will furnish Ms N N Chirwa with a detailed breakdown of the (a) funding that the Republic has received from the specified person since 1 January 2009 and (b) departments and/or entities to which the specified funds and/or donations were sent and/or directed by either his department or by the specified person as the donor; if not, why not, in each case; if so, by what date; (2) what (a) programmes has his department been involved in with the specified person and any related affiliations since 1 January 2009 and (b) programmes and/or associations does he envisage will take place with collaborative effort and/or through the funding of the specified person with the Republic in the current year and/or envisaged for a later period?

Reply:

1. The department is not aware of “historical concerns with regard to the influence of Mr Bill Gates over the South African healthcare system”. The Bill & Melinda Gates Foundation is one of many philanthropic organisations that contribute to healthcare across the globe. The Foundation “provides funding to organizations to achieve measurable impact in the fight against poverty, disease, and inequity around the world”, and “funds entrepreneurs, companies, and other organizations to create incentives that harness the power of private enterprise to create change for those who need it most.”

The Gates Foundation supports several programs in South Africa with its major focus on health. During the period 2009-2022, the Gates Foundation invested approximately $907 million dollars in South Africa to some 764 grantees and vendors (which include NGOs, universities, science councils, implementing partners, and manufacturers).

With specific reference to the vaccine programmes during COVID-19, departments and/or entities to which funds and/or donations were sent and/or directed by, include only one government entity, the SAMRC for the Sisonke healthcare worker COVID 19 vaccination programme, plus several private and non-government organisations.

With specific reference to SAHPRA since 1 January 2009 the Gates Foundation direct support to SAHPRA is $7.6million to date.

2. The Foundation has provided no direct funding to the NDoH since 1 January 2009 to date. The focus of the Foundation’s health investments is related to TB and HIV response and span the spectrum from discovery, translation science, product development and delivery of new interventions.

https://www.gatesfoundation.org/about/committed-grants?country=South%20Africa&region=AFRICA]

According to the Foundation the programmes and/or associations envisaged through the funding of the Foundation, include:

(i) in the current year:

  • Technical Support to the TB Programme
  • Technical Support on HIV quality improvement and HIV Prevention
  • Technical support to the DDG NHI
  • Catalytic support for scale up evidence-based TB and HIV interventions in South Africa
  • SAHPRA was supported with paying for external reviewers (both South Africa and non-South African) selected by SAHPRA to address the large backlog (+/- 16000 applications) inherited from the MCC at the request of the SAHPRA Board. This included all products as the Gates Foundation support of external reviewers was not product specific
  • Africa Resource Centre to provide technical assistance on Supply Chain management

(ii) envisaged for a later period:

  • Provision of catalytic support to implement evidence-based TB and HIV interventions in South Africa
  • Support to SAHPRA for digitisation of clinical trials records

END.

11 April 2023 - NW890

Profile picture: Clarke, Ms M

Clarke, Ms M to ask the Minister of Health

(1)What is the total number of (a) general practitioners, (b) specialist medical personnel, (c) surgeons and (d) paediatricians (i) nationally and (ii) in each province; (2) what is the ratio for each specified health professional to the population; (3) what total number of (a) doctors, (b) nurses and (c) psychologists were registered with the Health Professions Council of South Africa since 1 January 2013?

Reply:

  1. In accordance with the data as received from the Health Professions Council of South Africa (HPCSA), the following is the total number of

(a) General practitioners (i) nationally and (ii) in each province:

   

PRACTICE_FIELD

 

REGISTER_NAME

PROVINCE

MEDICAL PRACTITIONER

MEDICAL PRACTITIONER - Restricted Practice

Grand Total

MEDICAL PRACTITIONER

Eastern Cape

2,513

24

2,537

 

ex SWA

45

 

45

 

Foreign

473

1

474

 

Free State

1,186

18

1,204

 

Gauteng

9,669

41

9,710

 

Kwa Zulu Natal

5,582

21

5,603

 

Limpopo

1,480

23

1,503

 

Mpumalanga

1,457

25

1,482

 

North West

1,076

23

1,099

 

Northern Cape

610

36

646

 

UNKNOWN

2

 

2

 

Western Cape

5,939

5

5,944

 

Province n/a

383

2

385

MEDICAL PRACTITIONER Total

 

30,415

219

30,634

 

(b) Specialist medical personnel (i) nationally and (ii) in each province:

Grand totals for all Specialities and all Sub-subspecialties

   

PRACTICE_FIELD

 

REGISTER_NAME

PROVINCE

SPECIALIST

SUBSPECIALIST

Grand Total

MEDICAL PRACTITIONER

Eastern Cape

797

80

877

 

ex SWA

37

1

38

 

Foreign

344

27

371

 

Free State

634

70

704

 

Gauteng

5,534

853

6,387

 

Kwa Zulu Natal

2,415

348

2,763

 

Limpopo

259

14

273

 

Mpumalanga

330

9

339

 

North West

267

18

285

 

Northern Cape

139

9

148

 

UNKNOWN

2

1

3

 

Western Cape

3,698

625

4,323

 

Province n/a

162

25

187

MEDICAL PRACTITIONER Total

 

14,618

2,080

16,698

(c) Surgeons and (d) Paediatricians (i) nationally and (ii) in each province; -

   

S P E C I A L I T Y

 

REGISTER_NAME

PROVINCE

NEURO-

SURGERY

PAEDIATRICS

PAEDIATRIC SURGERY

SURGERY

Grand Total

MEDICAL PRACTITIONER

Eastern Cape

12

87

5

73

177

 

ex SWA

1

3

 

 

4

 

Foreign

2

27

1

15

45

 

Free State

13

64

4

47

128

 

Gauteng

107

575

27

404

1,113

 

Kwa Zulu Natal

41

279

11

245

576

 

Limpopo

5

44

 

15

64

 

Mpumalanga

7

28

 

22

57

 

North West

5

25

 

14

44

 

Northern Cape

2

15

 

7

24

 

UNKNOWN

 

 

 

1

1

 

Western Cape

59

402

15

281

757

 

Province n/a

3

15

 

13

31

MEDICAL PRACTITIONER Total

 

257

1,564

63

1,137

3,021

2. The current population for the Country is 60 604 087 as at March 2023. The table below provide the ratio breakdown per occupational category to the population.

Occupational Category

Sum - count

Total per 10 000 population

General Practitioners

30634

5.054774606

Specialist medical personnel

16 698

2.755259723

Surgeons

1 394

0.230017490

Paediatricians

1 627

0.268463742

 

3. The table below provide a breakdown of (a) doctors, and (c) psychologists who registered with the Health Professions Council of South Africa (HPCSA) since 1 January 2013

NB (b) Nurses do not register with the HPCSA.

Doctors

     

PRACTICE_FIELD

 

REGISTER_NAME

ORIGIN

CAT_FROM_

YEAR

General Practitioners

SPECIALIST

SUB

SPECIALIST

Grand Total

MEDICAL PRACTITIONER

SOUTH AFRICAN

2013

1,249

486

77

1,812

 

 

2014

1,244

497

100

1,841

 

 

2015

1,344

670

94

2,108

 

 

2016

1,333

700

72

2,105

 

 

2017

1,105

541

99

1,745

 

 

2018

1,418

519

87

2,024

 

 

2019

1,528

583

73

2,184

 

 

2020

1,583

423

95

2,101

 

 

2021

1,874

625

83

2,582

 

 

2022

2,339

654

83

3,076

 

 

2023

1,947

179

26

2,152

 

SOUTH AFRICAN Total

 

16,964

5,877

889

23,730

MEDICAL PRACTITIONER Total

 

 

16,964

5,877

889

23,730

 

psychologists

CAT_FROM_YR

                     

REGISTER_NAME

PRACTICE_FIELD

2013

2014

2015

2016

2017

2018

2019

2020

2021

2022

2023

Grand Total

PSYCHOLOGIST

CLINICAL PSYCHOLOGY

113

101

150

156

114

108

116

134

73

102

50

1,217

 

COMMUNITY SERVICE CLINICAL PSYCHOLOGY

87

155

146

118

108

124

119

74

99

99

50

1,179

 

COUNSELLING PSYCHOLOGY

47

51

49

41

52

65

67

54

63

63

9

561

 

EDUCATIONAL PSYCHOLOGY

51

70

47

62

62

74

54

48

73

67

22

630

 

INDUSTRIAL PSYCHOLOGY

98

116

125

127

121

89

115

95

125

88

15

1,114

 

NEUROPSYCHOLOGY

 

 

 

 

 

 

 

59

30

36

4

129

 

RESEARCH PSYCHOLOGY

19

13

25

20

18

7

11

8

8

14

1

144

 

(blank)

38

1

 

 

 

 

 

 

 

 

 

39

PSYCHOLOGIST Total

 

453

507

542

524

475

467

482

472

471

469

151

5,013

END.

11 April 2023 - NW880

Profile picture: Van Staden, Mr PA

Van Staden, Mr PA to ask the Minister of Health

(1)Whether, with reference to the current Eskom crisis and electricity blackouts at state and provincial hospitals, he will indicate (a) what the total amounts are that were spent on diesel for generators by each hospital in each province during the period 1 April 2022 up to 28 February 2023 and (b) if the generators at all hospitals across the Republic are in a workable condition; if not, why not, in each case; if so, what are the relevant details in each case; (2) whether he will make a statement on the matter?

Reply:

  1. (a) See below the breakdown on the expenditure for the diesel consumption by the generators in each province:

Annexure A is attached and it covers a breakdown expenditure for diesel usage by generators for each hospital in the Republic.

b) Yes, the generators are in a workable condition.

2. I will not be making a statement on this matter.

END.

11 April 2023 - NW995

Profile picture: Mkhonto, Ms C N

Mkhonto, Ms C N to ask the Minister of Health

In light of the ongoing strike by members of the National Education, Health and Allied Workers’ Union, (a) which measures of intervention have been put in place to mitigate the absence of health workers from their service points and (b) what is the total number of patients who have died as a result of the strike?

Reply:

a) The intervention measures are coordinated at local facility level, supported by the District and Provincial administration. During the NEHAWU led strike, the clinical leadership at each facility put in place mechanisms to reduce the impact, including some staff volunteering to work longer hours, some staff performing duties not normally allocated to them e.g. feeding of patients, cleaning the wards. This included a real-time system of diverting emergencies to health facilities that were not or were less severely affected by the strike activities.

The intervention measures also included the National Department of Health led by the Minister, Provincial Departments of Health led by the MEC’s and senior officials in providing support at facility level. The National Health Council also ensure that a coordinated strategy is developed and implemented to support local facility management including monitoring and managing the strike. In selected instances, assistance was sought and received from South African Military Health Services for the most hard hit hospitals.

b) So far, only six (6) deaths are alleged to be attributed to the strike. However, these are subject to ongoing investigation.

END.

11 April 2023 - NW878

Profile picture: Van Staden, Mr PA

Van Staden, Mr PA to ask the Minister of Health

(1)Whether, with reference to the current Eskom crisis and electricity blackouts at both state and private hospitals and/or clinics across the Republic, he will meet with Eskom and/or municipalities to find agreement on exempting all private hospitals and clinics across the Republic from load shedding; if not, why not, in each case; if so, by what date will such discussions take place; (2) whether he will make a statement on the matter?

Reply:

1. I have directed the Director General of Health to meet with ESKOM to jointly seek interventions to mitigate against loadshedding. The first engagement took place on 22 September 2022. The meetings with Eskom are happening on a regular basis to seek for more exemptions of healthcare facilities. There are further ongoing engagements with both COGTA and various municipalities regarding additional exemptions for both private and public health care facilities from the grid.

2. No.

END.

05 April 2023 - NW760

Profile picture: Clarke, Ms M

Clarke, Ms M to ask the Minister of Health

(1)For each province, what (a) total number of nurses have been terminated due to their registration lapsing at the Health Professions Council of South Africa and (b) has been the reasons for the registration lapses; (2) given the critical shortage of nurses, what steps have been taken to assist nurses with their lapsed registration?

Reply:

1. The honourable member should note that nurses do not register with the Health Professions Council of South Africa (HPCSA), but with the South African Nursing Council (SANC).

(a)-(b) As per the information received from the SANC, the total number of nurses whose membership was terminated or their names removed due to their registration lapsing is 21 332 over the period of 2021 to 2022, as per the table below. The reasons are also reflected in the very table below.

Table 1.

 

Reason for removal

Province

Deceased

Removed - Administratively

Removed - At own request

Removed - Disciplinary

Removed - Non-payment of annual fee

Grand Total

Eastern Cape

14

2

8

1

3020

3045

Free State

 

 

3

 

1086

1089

Gauteng

24

3

32

5

5257

5321

KwaZulu-Natal

39

5

27

0

4708

4779

Limpopo

16

 

2

3

1622

1643

Mpumalanga

2

2

1

0

929

934

North-West

8

 

5

 

1362

1375

Northern Cape

1

 

0

1

343

345

Outside RSA

 

 

4

 

84

88

Western Cape

7

6

21

0

2679

2713

Grand Total

111

18

103

10

21090

21332

2. In order to assist nurses with their lapsed registration, the Department has successfully signed Resolution 3 of 2019 at the Public Health and Social Development Sectoral Bargaining Council (PHSDSBC) which is an agreement on payment of annual statutory registration fees in respect of health and social development professionals (including Nurses)

The objective of the Resolution amongst others is to:

- Introduce mandatory deductions of professional registration fees from salary of employees by PERSAL as required by the respective statutory professional bodies in the Health and Social Development Departments.

- Assist in the monitoring of potential risks and compliance with registration requirement for appointment and practice as stipulated in the respective Statutory Professional bodies in the departments

END.

05 April 2023 - NW763

Profile picture: Wilson, Ms ER

Wilson, Ms ER to ask the Minister of Health

(1)What number of times has the anti-corruption forum within the health sector (HSACF) met in each year since it was established in 2018; (2) what (a) number of allegations of corruption have (i) been referred to the forum and (ii) resulted in investigations by the HSACF in each year since 2018 and (b) was the nature of the allegations, such as fraud, maladministration and/or corruption; (3) what number of the specified investigations have resulted in (a) successful criminal prosecutions, (b) civil recoveries, (c) medical practitioners struck off the roll, (d) medical aid scheme sanctions emanating from HSACF referrals in each case, (4) what specified preventative and/or risk-management measures were implemented by the HSACF?

Reply:

1. The Health Sector Anti-Corruption Forum (HSACF) has convened its meetings on Nine (09) occasions since 2018, below is the details of the meetings:

#

Date of Meeting

1.

23 August 2018

2.

20 November 2018

3.

27 November 2019

4.

21 May 2019

5.

30 June 2020

6.

02 December 2020

7.

29 June 2021

8.

30 March 2022

9.

21 September 2022

 

In addition, the HSACF has established the Steering Committee that has been mandated to assess all health-related corruption allegations that have been reported. The Steering Committee serves as an operational structure of HSACF and meets more frequently or as and when there are new allegations that has been reported, which requires to go through assessment process.

2. (a) Number of allegations of corruption have (i) been referred to the forum and (ii) resulted in investigations by the HSACF in each year since 2018.

  • A total number of eleven (11) allegations were reported to the HSACF in 2018/19/20. All allegations were referred to the relevant entities who are part of the HSACF for formal investigations as per their legislative mandate.
  • A total number of twelve (12) allegations were reported to the HSACF in 2020/21. All allegations were referred to the relevant entities who are part of the HSACF for formal investigations as per their legislative mandate.
  • A total number of five (05) allegations were reported to the HSACF in 2021/22. All allegations were referred to the relevant entities who are part of the HSACF for formal investigations as per their legislative mandate.
  • One (01) allegation was reported to the HSACF in 2022/23. The allegation was referred to the relevant entity who is part of the HSACF for formal investigations as per their legislative mandate.

3. The HSACF has registered quite a significant investigations outcomes or successes in twelve (12) matters that were reported to the Forum and formally investigated by member entities. The below table highlight some of the successes in terms of criminal prosecution, civil recoveries, and medical aid sanctions:

#

Entity Investigated

Investigation Outcomes

1

Health Professional Council of South Africa

  • Presidential report submitted in May 2022
  • DC referrals 19
  • NPA referrals 21
  • SARS referrals 2
  • OHSC referral 1

2

Provision of Aero Medical & Patient Transport – NW

  • Freezing order of former HOD pension to the value of R2 125 113,58
  • R30 000 000 civil proceeding have been instituted.
  • HOD has been referred for disciplinary and has been dismissed on 13 January 2020
  • NPA criminal referral for 2 officials (Thapelo Buthelezi & CFO Mr Lekalakala)
  • Disciplinary referral made for CFO who facilitated the irregular payments to Buthelezi EMS
  • Civil proceedings underway to the value of R204 million are being instituted against Buthelezi EMS

3

Provision of Aero Medical & Patient Transport – FS

  • 10 disciplinary referrals.
  • 8 referrals for administrative action.
  • 5 referrals to the NPA

4

National Health Laboratory Services

  • 8x Disciplinary Referrals
  • 11x NPA Referrals
  • 8x finalised investigations
  • 1 x Civil referral: Review application against 8 companies: R172 million. Preservation order obtained

5

Council for Medical Schemes

  • 13 x disciplinary referrals relating to 2 individuals.
  • 1 x criminal referral relating to 18 individuals.
  • 4 x systemic recommendations
  • 53 x investigations concluded (lifestyles, complaints, procurement, regulatory reviews)

6

Office of the State Attorney

Focus Area 1: Maladministration in connection with the affairs of the office of the State Attorney in relation to― (a) legal services that were provided, or procured, by the office of the State Attorney in the performance of its functions as contemplated in section 3 of the State Attorney Act, 1957 (Act No. 56 of 1957), on behalf of― (i) the Gauteng Department of Health and the Eastern Cape Department of Health in respect of claims based on medical negligence;

Legal Practitioners

  • Civil litigation instituted to the value of R82 994 347 for potential cash and/or assets recovered.
  • R 217 000 Acknowledgement of Debt - AoD signed
  • 8x disciplinary referrals
  • 15x administration actions referrals
  • 12x criminal referrals

Medical negligence cases in Court.

  • Civil litigation instituted to the value of R412 549 298 for potential cash and/or assets recovered.
  • Rand value of potential loss prevented to the amount of R412 549 298
  • 14x disciplinary referrals made.
  • 13x administrative action referrals
  • 7x criminal prosecution referrals
  • Rand value of matters in respect of which evidence was referred for the institution or defence/opposition of civil proceedings to the value of R412 549 298

Focus Area 2: Maladministration in connection with the affairs of the office of the State Attorney in relation to ― the South African Police Service in respect of claims based on wrongful arrest or detention, assault, or malicious prosecution.

  • Rand value of potential cash and/or assets to be recovered to the value of R1 600 000.00
  • Rand value of potential loss prevented to the amount of R25 747 581
  • 1x disciplinary referral made.

Focus Area 3: The procurement of legal services, as contemplated in paragraph 2(a) of this Schedule, by the office of the State Attorney, or payments which were made in respect thereof, in a manner that was―

(a) not fair, competitive, transparent, equitable or cost-effective; or (b) contrary to manuals, policies, procedures, prescripts, instructions or practices of, or applicable to the office of the State Attorney, and any related unauthorised, irregular or fruitless and wasteful expenditure which the Department or the State incurred as a result thereof.

  • Rand value of potential cash and/or assets to be recovered to the value of R4 146 476 079.
  • Rand value of actual cash and/or assets recovered to the value of R2 228 773.44
  • 2x disciplinary referrals
  • 5x criminal prosecution referrals

Focus Area 4: Irregular conduct by— (a) employees or officials of the office of the State Attorney; or (b) any other person or entity, relating to the allegations referred to in paragraphs 2 or 3 of this Schedule."

  • 27 criminal prosecution referrals
  • 33 Administrative action referrals
  • 28 disciplinary referrals
  • 1x SARS referral
  • 12x systemic recommendations made.

7

South African Health Product Regulatory Authority

  • 5x criminal referral letters have been for referred to NPA to institute criminal prosecutions for fraud in respect of 5 officials who caused the issuing of irregular licenses.
  • 5x disciplinary action referral letters (DCs) have been referred to the South African Products Regulatory Authority (SAHPRA) so that they can be disciplined in line with their policies and the Public Service Act.
  • The investigating team is busy drafting the Final Presidential Report.

8

National Department of Health Medico Legal Claims

  • 18 legal practitioners are being investigated by the Special Investigating Unit (SIU) that assisted the Office of the State Attorney in rendering legal services in respect of medical negligence claims on the Gauteng Department of Health and the Eastern Cape Department of Health.
  • 17 claims of legal practitioners still need to be verified by Legal Tax Bill Consultants.
  • The SIU is also busy litigating cases involving Hypoxic Ischemic Encephalopathy (HIE) with acute profound & partially prolonged in courts costing more than R203 549 298.
  • Hypoxic Ischemic Encephalopathy (HIE) with acute profound & partially prolonged. Hypoxic Ischemic Encephalopathy (HIE) with acute profound & partially prolonged.
  • The SIU has investigated Janilite (PTY) Ltd which acted as intermediary in both ECDH & GDH and a settlement of R2 228 773.44 was agreed by the departments with the assistance of the SIU.

9

National Department of Health

  • The docket has been submitted to the State Prosecutor for decision, this matter relate to senior officials who defrauded the Department of Health millions in subsistence and travel irregularities.

10

Government Employee Medical Scheme (GEMS)

  • The docket is almost complete, the Investigator is working on concluding financial report based on financial statements. The docket will soon be submitted to State Prosecutor for decision

11

COVID-19 National Proclamation

  • The final report was submitted to the President in June 2022. The legal outcomes have been presented to Parliament oversight Committees

12

Pretoria Eye Institute

  • Acknowledgements of debts was signed on this matter with some of the medical schemes that are affected who were involved in claim irregularities.

4. Specified preventative and/or risk-management measures were implemented by the HSACF

  1. A series of webinars were successfully rolled out in 2020/21FY under the banner of HSACF Corruption Prevention Program with the following objectives:
  • To create public awareness about corruption in the health sector
  • To profile the Health Sector Anti-Corruption Forum (HSACF)
  • To raise awareness about whistleblowing and witness protection

Amongst the thematic areas in relation to health sector corruption that were discussed include the following:

  • The corruption pandemic in South Africa’s health sector
  • National Health Insurance (NHI) and its vulnerability to corruption
  • Combatting corruption in the private health sector
  • When corruption and Covid-19 intersect
  • Unpacking whistleblowing protection in South Africa

2. Collaboration with UNODC to implement corruption prevention programs in South Africa’s health sector.

  • The HSACF is collaborating with the UNODC to implement corruption prevention initiatives in the health sector, which include strengthening whistleblowing/reporting mechanism and corruption risk assessments. Two (2) health sector entities were identified to implement these projects.
  • These entities include HPCSA where a pilot project will be implemented on strengthening their internal whistleblowing/reporting channels and National Department of Health where corruption risk assessments will be implemented in particular around procurement.

3. Corruption Risk Mitigation Plan for COVID-19 Vaccine Roll-Out

  • The COVID-19 Corruption Risk Mitigation Plan (CRIMP) was initiated to supports the National Covid-19 Vaccine Roll-Out Plan, led by the Inter-Ministerial Committee, chaired by the Deputy President
  • The key objective of CRIMP was to develop and implement a specific anti-corruption lens on the roll-out of the vaccine taking lessons from the PPE investigations.
  • The development of the CRIMP was led by DPME, working closely Health Sector Anti-Corruption Forum, convened by the SIU under the ACTT Prog 4.

The specific purpose of CRIMP was to enhance and complement existing efforts by providing:

  • Framework and template to assess COVID-19 Vaccine corruption risks.
  • Consolidate and Assess (“hack”/stress test) the workstream plans into a single, living anti-corruption risk mitigation plan.
  • Act as coordination interface between the IMC work streams and specialist anti-corruption capacity (such as ACTT and its Fusion Centre) where required.
  • Act as coordination interface with civil society, business, and labour; and optimise the existing mechanisms (e.g., with the SIU led Health Sector Anti-Corruption Forum) on broadening the anti-corruption response.

END.

05 April 2023 - NW828

Profile picture: Hlengwa, Ms MD

Hlengwa, Ms MD to ask the Minister of Health

With regard to the reported increase in Cholera outbreaks in the Republic as of 28 February 2023, with a total of six confirmed cases, including one death, having been reported in Gauteng (details furnished), what steps is his department taking towards containing the outbreak?

Reply:

Steps the department has taken to raise awareness amongst the public about the prevention and management of cholera.

After the WHO reported that the cholera outbreak had occurred in Malawi and Mozambique, and other countries in the SADC regions, the National Department of Health alerted all the provinces about the cholera outbreak. The provinces were requested to use the risk assessment and contingency plan tools to assess their capacity for preparedness and readiness for cholera outbreak. The National Department of Health met with the provinces to discuss the plans and actions required in preventing and controlling the spread of cholera. Steps that were taken to raise awareness amongst the public about the prevention and management of cholera are outlined below as follows:

a) Prevention and Control

The National Department of Health has activated the Multisectoral National Outbreak Response Teams (MNORT), which includes members from the National Department of Health, National Institute for Communicable Diseases (NICD), provinces and the World Health Organization (WHO). The focus areas include surveillance; water, sanitation and hygiene; social mobilisation; Risk Communication and Community Engagement. The MNORT meetings are held on weekly basis (Fridays) to discuss the ongoing cholera outbreak in the country.

  • A public announcement was made to inform and alert the public about the outbreak of cholera.
  • All provinces received cholera guidelines and case investigation forms.

b) Surveillance

Disease surveillance, preparedness and outbreak response activities to detect outbreaks rapidly are ongoing in the provinces and at national level.

c) Water and sanitation interventions

The long-term solution for cholera control lies in access to safe drinking water and adequate sanitation. Actions targeting environmental conditions including the implementation of water, sanitation and hygiene (WASH) solutions to ensure use of safe water, basic sanitation and good hygiene practices in cholera hotspots are being addressed. 

d) Community Engagement

Community engagements were conducted in all provinces, and distribution of Information, Education, and Communication (IEC) pamphlets and posters to teach the public about potential risks, symptoms of cholera, precautions to take to avoid cholera, when and where to report cases and to seek immediate treatment when symptoms appear continues to take place.

Awareness was raised about prevention through:

  • Development and distribution of posters and flyers
  • Giving health talks on community radio stations
  • Cholera prevention and management messages were shared using departmental social media.
  • Continuous health education is conducted in health facilities.

END.

05 April 2023 - NW764

Profile picture: Wilson, Ms ER

Wilson, Ms ER to ask the Minister of Health

Whether he will provide Mrs E R Wilson with a list of the name of each (a) hospital and (b) clinic that is (i) currently exempted from load shedding and (ii) next in line to be exempted in each province in each case; if not, why not; if so, (aa) what are the relevant details and (bb) on what date will each hospital and clinic be exempted?

Reply:

a) Not all hospitals have been exempted from the load-shedding. However, the National Department of Health has provided Eskom with a total of 213 hospitals to be considered for possible exclusion from loadshedding. About 67% of these hospitals are supplied by municipalities while Eskom supplies about 33% of the identified hospitals. Out of the 213 hospitals, 76 hospitals have been exempted of which 26 are directly supplied by Eskom and 50 by Municipalities. The number of hospitals exempted to date have doubled since the meeting held on 22 September 2022 between Eskom and National Department of Health. To date, there are 7 hospitals exempted in Eastern Cape, 9 in Limpopo, 15 in KZN, 4 in Mpumalanga, 4 in Western Cape, 2 in Northern Cape, 3 in North West, 14 in Free State, and 18 in Gauteng provinces. Should there be a need of hospitals names per province, a breakdown list of hospitals is available on request.

b) Load-shedding has a negative impact to the provision of health services at primary health facilities, hospitals, community health centres, clinics, EMS centres including the forensic laboratories. In order to reduce the impact of load-shedding, the National Department of Health is seeking for the financial support to assist with the effective delivery of the following areas:

(i) Additional funding support for fuel, oil including the servicing of generators. The hospitals have been forced to use its budget on fuel, oil and medical gas just to keep healthcare facilities running. With persistent stage 6 load-shedding, greater energy demand is placed on generator capability which requires increased fuel consumption and vast expenditure.

(ii) Additional funding support for the installation of dedicated lines for certain key hospitals that are deeply embedded within the Eskom’s or Municipal networks rendering exclusion impossible in their current state as bigger loads are to be exempted.

(iii) Additional funding support for the roll-out of the solar energy + battery storage as back-up supply to all the clinics, CHC’s, hospitals, EMS centres including the forensic laboratories.

END.

05 April 2023 - NW761

Profile picture: Clarke, Ms M

Clarke, Ms M to ask the Minister of Health

(1)With reference to his reply to question 2091 on 17 June 2022, and given the vacancy rate of 27 137 doctors, nurses and Emergency Medical Services personnel in the Republic, (a) what are the main reasons for the massive number of vacancies, especially nurses, (b) what steps have been taken by his department to fill the specified positions, (c) in which provinces will the positions be filled and (d) what total number of each position will be filled; (2) what (a) are the reasons that medical students are still struggling to be placed into internships, given the specified vacancies and (b) practical solutions and/or plans will be put in place to ensure that no one is left behind; (3) what (a) are the reasons that intern doctors are still struggling to be placed into community service, given the vacancies and (b) practical solutions and/or plans will be put in place to ensure that no one is left behind; (4) given the total number of foreign medical personnel employed in the Republic, what are the reasons that South African medical personnel who qualified and trained in foreign countries are struggling to obtain accreditation from the Health Professions Council of South Africa?

Reply:

1. The response to parliamentary question 2091 that which was provided on 17 June 2022 indicated a total vacancy posts of 27 137 for doctors, nurses and emergency medical services personnel in the Republic. As of 28 February 2023, there were 18 804 vacant posts of doctors, nurses and medical care personnel. This demonstrates a 31% achievement rate in the filling of vacant posts.

a) The main reason for the recorded vacant posts is general budget cuts introduced by National Treasury. These cuts also affect Compensation of Employment (CoE) negatively resulting in not all posts being filled simultaneously.

b) As demonstrated above in order to reduce the vacancy rate by 31%, the Department introduced several interventions which amongst others, include:

  • (i) Prioritisation of the posts in the Annual Recruitment Plan – where funding permits;
  • (ii) Prioritisation of the posts for conditional grant funding;
  • (iii) Filling of replacement posts considered and approved weekly;
  • (v) Advertisements published National wide through print media.

c) Filling of these vacant posts will be prioritised in all provinces as per above method to ensure that there is no over expenditure of Compensation of Employment (CoE).

d) Posts are prioritised according to the availability of funding and the Annual Recruitment Plan as informed by the service delivery model.

2. (a) The Department working together with Provincial Departments of Health and National Treasury has put in place mechanisms to ensure that all eligible South African Citizens and Permanent Residents are allocated to accredited medical internship positions within the Cycle that applicants qualify for. This is evident by the conclusion of allocating 2 505 medical interns applicants in the January Annual Cycle 2023.

Only 55 applicants are still to be allocated as they were not eligible due to various reasons e.g., applicants declining the posts and preferring to wait for the next cycle.

(b) All eligible applicants will again be given an opportunity during the Midyear Cycle which will start on the 1 July 2023.  

3. (a) The Department working together with Provincial Departments of Health and National Treasury has put in place methods to ensure that all eligible South African Citizens and Permanent Residents are allocated to medical community service positions within the Cycle applicants qualify in. This is evident by the conclusion of allocating 2 509 medical community service applicants in the January Annual Cycle 2023.

(b) All other eligible applicants, who met the allocation requirements later, will again be given an opportunity during the Midyear Cycle which will start on the 1 July 2023.  

(4)   Registration of foreign qualified medical applicants with the Health Professions Council of South Africa (HPCSA) is a multi-layered process. The HPCSA has to satisfy itself that applicants studied in legally recognized Institutions, by both the health and regulatory authorities of the countries of training. Applicants are required to submit several documents that will assist the HPCSA to establish their competency, including the hours that they would have spent in training and the domain training completed. As most of them study in non-English speaking countries, for example China, Russia and Turkey, documents have to be translated into English and notarized before the HPCSA  can submit them to relevant committees of the board to make a determination about the equivalence of their training to that provided in South Africa. Any delays in one of the steps in this process ordinarily lengths the processing of applications.

END.

05 April 2023 - NW762

Profile picture: Wilson, Ms ER

Wilson, Ms ER to ask the Minister of Health

(1)Whether the Republic attended the first draft deliberations on the Pandemic Treaty of the World Health Organisation on 1 August 2022; if not, why not; if so, who was the Republic’s representative at the deliberations; (2) whether the Republic submitted observations and proposed amendments to the draft before the end of October 2022; if not, why not; if so, what were the relevant details of all the observations and proposed amendments; (3) whether the Republic attended the second draft deliberations and adoption on 7 December 2022; if not, why not; if so, who were the Republic’s representatives?

Reply:

1. The Pandemic Treaty deliberation are still in the conceptualisation of a Zero Draft framework and negotiations have not yet commenced. South Africa participated in discussions focussing on the development of the Conceptual Draft Document which is a framework and outline of the envisaged pandemic instrument that looks at background, methodology and approach to be used during the development of the negotiation tool. South Africa was represented by our Health Attache to Geneva and the United Nations, Ms Lebogang Lebese, who is based in the South African Mission in Geneva.

2. South Africa is championing the cause of access and equity in pandemic preparedness and response. Therefore, the technical input to the Conceptual Zero draft referred to above, was centred around strengthening of the framework in the areas of “operationalisation of the instrument and on achieving equity” with emphasis on seven types of equitable access on Tools; Essential Supplies (strengthening supply chains and shortening supply lines); Financing; Vaccines; Health Workforce; Disease Surveillance and detection of zoonotic and environmental risks; and Equitable ramping up and diversification of manufacturing.

3. The Pandemic instrument discussions have not yet reached the stage of discussing a second draft. South Africa participated in further discussion on developing the Conceptual Zero Draft framework and was represented by our Health Attache, who was also joined by our Ambassador Mr Mxolisi Nkosi, the South African Permanent Representative to the United Nations office in Geneva and other international organisations in Switzerland.

END.

05 April 2023 - NW814

Profile picture: Hlengwa, Ms MD

Hlengwa, Ms MD to ask the Minister of Health

(1)Whether, in view of Gauteng reportedly having 47 confirmed cases of measles, North West 157, Mpumalanga 97 and Limpopo with the highest number of infections recorded at 167, his department is taking any steps towards containing the outbreak; if not, why not; if so, what steps; (2) whether his department has considered an immunisation drive at all schools, primarily primary schools; if not, why not; if so, what are the relevant details?

Reply:

(1) The Department is taking the following epidemiological responses to contain measles outbreak:

a) Measles campaign vaccination

Nationwide mass measles vaccination campaign is conducted in all 52 districts to contain outbreak by administering additional measles dose to all children from 6 months to 15 years regardless of their previous history of measles vaccination.

b) Epidemiological and clinical management of cases and contacts.

  • All confirmed measles outbreak cases are epidemiologically investigated through field visits, and support to the affected areas are provided by both provincial and national teams.
  • All suspected measles outbreaks are confirmed by the National Institute of Communicable Diseases (NICD) to be due to measles virus infection.
  • There is clinical management of cases including isolation, administration of Vitamin A, management of complications and follow-up of close contacts.

c) Intensified Measles surveillance

  • Measles surveillance is intensified to actively seek additional cases both in public and private health facilities.
  • Health workers are urged to be on the alert to detect, investigate and appropriately manage cases.
  • There is an ongoing full investigations of possible outbreaks in non-affected districts and urgent measures to strengthen surveillance are implemented.

d) Enhanced communication

Various Risk Communication and Community Engagement platforms are used to raise awareness in the communities about the disease and its prevention - and alerted to report people with measles symptoms and to ensure that children are fully vaccinated according to the national schedule.

e) Establishment of Outbreak Response teams

Outbreak teams have been established at district, provincial and national levels. The following work streams have been established within the national outbreak response team:

  • Case management (including contact tracing)
  • Surveillance and reporting
  • Risk Communication and Community Engagement
  • Supplementary vaccination campaign planning and execution – includes vaccine procurement and data management sub-streams.

(b) Children from 6 months to 15 years are given an additional measles dose at Early Development Centres, Primary schools and High schools.

END.

24 March 2023 - NW610

Profile picture: Wilson, Ms ER

Wilson, Ms ER to ask the Minister of Health

(1)For each year since 2018 in each province, (a) how does his department identify fraudulent claims, (b) what total (i) number of fraudulent claims have been paid out and (ii) amount of the specified money has been recouped and (c) what (i) are the top causes and/or reasons for medico-legal claims such as cerebral palsy and (ii) is the total number in each case; (2) whether any of the provinces are using manual tracking to track medico-legal claims; if so, why has an electronic tracking system not been implemented; (3) whether any of the provinces are using electronic tracking to track medico-legal claims; if so, why is manual tracking still used in some cases even though an electronic tracking system has been implemented?

Reply:

1. (a) In 2019, the National Department of Health appointed Service Providers to conduct forensic investigations. One of the responsibilities has been to identify any fraudulent claims. The reports of these investigations are the basis of the current SIU investigations in all the Provinces in line with the Proclamation.

The following table reflects the details in this regard:

Province

Number of fraudulent claims paid out

Amount of money recouped

Top causes and/or reasons for medico-legal claims

Total number in each case

Eastern Cape

Nil

Nil

Obstetrics & Gynae related

1135

     

Orthopaedic,

92

     

Surgical

42

     

ICU related

46

     

Other

399

Free State

Nill

Nill

Cerebral Palsy

132

     

Surgical complications

53

     

Gynae & Obstetrics

84

     

Wrong diagnosis/ medication

63

Gauteng

Nill

Nill

Prolonged labour

18

     

Brain damage

93

     

Genetics

2

     

Injury or impairment

66

     

Multiple prior pregnancies

18

     

Unwanted pregnancy

5

     

Respiratory distress syndrome

1

     

Prior damage to uterus

25

     

Foreign object found in birth canal

9

     

Bacterial infection

26

Limpopo

Nill

Nill

-

-

Kwazulu-Natal

   

-

-

Mpumalanga

Nill

Nill

Cerebral Palsy

613

     

Orthopaedics

391

North West

-

-

-

-

Northern Cape

Nil

Nil

Cerebral Palsy

33

     

Surgery

9

Western Cape

Nill

Nill

Obstetric other mishaps

20%

     

General surgical

10%

     

Trauma

5%

     

Neurosurgery

5%

     

Orthopaedics

5%

     

Ophthalmology

5%

     

Paediatrics

5%

     

Anaesthetics

5%

     

Other

10%

2. According to Provinces, they use both manual and electronic tracking systems. Most of the Provinces have their inhouse electronic system.

3. According to the Provinces, there are those that are using their own electronic system. These include Eastern Cape Mpumalanga, Limpopo and Western Cape. Kwazulu-Natal, Free State, Gauteng, Northern Cape and North West are using the Case Management System.

END.

24 March 2023 - NW609

Profile picture: Wilson, Ms ER

Wilson, Ms ER to ask the Minister of Health

For each province and year since 2018, what total (a) number of (i)(aa) medico-legal claims have been filed and (bb) the specified claims have been paid out, distinguishing between (aaa) settlements and (bbb) court-ordered payments, (ii) claims were awarded based on lost patient files and (iii) duplicate claims have been filed and (b) amount has been spent on legal costs?

Reply:

According to the information received from our Provincial Departments of Health, the table below reflects the details in this regard:

PROVINCE

Number of medico-legal claims filed

Number of claims paid out

Number claims paid by way of settlements

Number of claims been paid by way of court order

Number of claims awarded based on lost patient files

Number of duplicate claims filed

Total (b) amount spent on legal cost

Eastern Cape

1714

331

0

331

0

0

R 281 368 162

Free State

345

25

25

0

0

0

R 31 619 758.74

Gauteng

384

-

0

0

0

0

R 996 278 397.03

KwaZulu- Natal

833

148

0

148

0

0

R 417 603 116.00

Limpopo

1147

41

4

37

0

0

-

Mpumalanga

756

79

30

49

27

0

R 358 971 364, 00

Northern Cape

83

25

25

0

7

0

R 37 921 415.00

North West

351

 

16

10

0

0

R112 273 309.00

Western Cape

273

137

137

0

0

0

R71 161 000.00

Table 1.

END.

23 March 2023 - NW568

Profile picture: Xaba, Mr NV

Xaba, Mr NV to ask the Minister of Health

Whether, with regard to the devastating health and socio-economic impact of the COVID-19 pandemic, the Republic has been party to any international treaties on pandemics apart from the COVAX Facility that the Republic is part of; if not, what is the position in this regard; if so, what gaps have been identified for strengthening?

Reply:

The Republic has participated in several multilateral platforms dealing with Pandemic Preparedness, Prevention and Response (PPPR). These platforms include the Access to COVID-19 Tools Accelerator (ACT-A) Facilitation Council, the World Health Organisation-led International Health Regulations (IHR)(2005) review processes, and the World Health Organisation-led Intergovernmental Negotiating Body (INB) that will consider the envisaged international pandemic treaty that is still to be negotiated. The ACT-A Facilitation Council (FC) was launched in April 2020 and established in September 2020 to facilitate the work of the ACT-A partnership and was Co-Chaired by South Africa and Norway are the Co-Chairs of the FC. The ACT-A was established
to enable an effective and equitable global response to the COVID-19 pandemic and was established at a time of urgency and uncertainty – less than three months after the World Health Organisation (WHO) determined that the outbreak of the 2019 novel coronavirus (2019-nCoV) was a Public Health Emergency of International Concern on January 30, 2020. It brought together governments, scientists, businesses, civil society, and philanthropists and global health organizations such as the World Health Organisation (WHO), the World Bank, the Global Fund, the Bill & Melinda Gates Foundation, CEPI, FIND, Gavi, Unitaid, and Wellcome.


The ACT-A was responsible for mobilising Medical Countermeasures (MCMs) as tools that were deployed for interventions and treatments used to prevent or mitigate the effects of a pandemic or other public health emergency of international concern such as vaccines, therapies, medical devices, tests and other diagnostic tools, and personal protective equipment. The ACT-A Facilitation Council commissioned an independent external evaluation. The evaluation Report assessed 24 evaluation questions across six areas namely: 1. Mandate; 2. Set-up and structure; 3. Resource mobilization and
financing; 4. Achievements; 5. Gaps and missed opportunities; and 6. Way forward. The evaluation Report was published on 10 October 2022.

https://www.who.int/publications/m/item/external-evaluation-of-the-access-to-covid-19-tools-accelerator-%28act-a%29.

South Africa is also participating in the IHR-2005 review process through the Bureauof the Working Group on Amendments to the International Health Regulations (2005) coordinated by the WHO. The review process is still in the early stages. Member States and relevant stakeholders have been invited to express their general views on the proposed amendments, including on Article 2 “Purpose and scope” and Article 3 “Principles” of the IHR. Member states will in future be invited to identify areas where there may be convergence and also the opposite, and to identify any priorities for addressing the amendments including on areas of potential overlap with the work of the Intergovernmental Negotiating Body (INB). The Director-General of the WHO will
communicate the package of targeted amendments before the opening of the Seventy-seventh World Health Assembly as per Article 55(2) of the IHR.
In addition, South Africa is participating in the intergovernmental negotiating body (INB) consists of WHO Member States and which is Co-Chaired by South Africa and Netherlands. The INB is involved in the discussion of the Pandemic Instrument. The deliberations are currently still at the stage of the conceptualisation of a Zero Draft framework. The Zero Draft document is a framework and outline of the envisaged pandemic instrument that looks at background, methodology and approach to be used during the development of the negotiation tool. The negotiations have not yet commenced but South Africa is participated in discussions focussing on the development of the Conceptual Draft Document. The proposed accord would take the lessons learned from the COVID-19 pandemic and use them to prepare better in the areas of Pandemic Preparedness, Prevention and Response (PPPR). The issue of equity has been identified as one of the key principles that must be considered in future deliberations of the new accord. Negotiations on the instrument will only commence in the latter part of 2023.

END.

23 March 2023 - NW759

Profile picture: Clarke, Ms M

Clarke, Ms M to ask the Minister of Health

Whether the SA Health Products Regulatory Authority is allowing the importing of Meloxicam BP for other (a) purposes and/or (b) companies besides certain companies (names furnished); if not, what is the position in this regard; if so, to which other companies?

Reply:

(a) Based on response received from the South African Health Products Regulatory Authority (SAHPRA), the importation of Meloxicam is allowed as a substance by companies that are licenced to (a) import as per Section 22C (1)(b) of the Medicines Act and Regulation 6 of the regulations published in terms of the Medicines Act.

There are requirements in terms of the possession, manufacture or selling of a scheduled substance. Section 22A (1) of the Medicines Act, states that no person shall sell, have in his or her possession or manufacture any medicine, Scheduled substance, medical device or IVD, except in accordance with prescribed conditions. Section 22A(5) further provides conditions regarding the sale of schedule 3 and mentions the persons that may sell these substances. Persons allowed to sell Schedule 3 substances include registered pharmacy personnel, manufacturers, wholesalers and other health care professionals that are adequately licensed in terms of Section 22C(1)(a) of the Medicines Act.

SAHPRA requires substances to be sold according to the requirements of the Medicines Act and its regulations. It should be noted that Meloxicam is not subject to the requirements of Schedule 3 when it is specifically packed, labelled or sold for industrial purposes including the manufacture or compounding of consumer products which have no pharmacological action or medicinal purpose, or if used for analytical laboratory purposes.

(b) SAHPRA regulates persons who are licensed to import scheduled substances and its mandate includes enforcing the requirements of the Medicines Act in terms of control of scheduled substances for medical use. SAHPRA does not regulate companies involved in the use of meloxicam for industrial purposes including the manufacture or compounding of consumer products which have no pharmacological action or medicinal purpose, or if used for analytical laboratory purposes.

END.

23 March 2023 - NW652

Profile picture: Chirwa, Ms NN

Chirwa, Ms NN to ask the Minister of Health

What (a) is the current waiting list of wheelchairs in each province, (b) steps has he taken to expedite the delivery thereof and (c) is the time frame within which he intends to resolve the crisis of wheelchair shortages?

Reply:

a) The waiting list of wheelchairs in each province is as follows:

Province

Wheelchair waiting list

Eastern Cape

5140

Free State

0

Gauteng

181

KwaZulu-Natal

166

Limpopo

789

Mpumalanga

67

North-West

244

Northern Cape

166

Western Cape

0

b) Steps taken to address the waiting list.

According to the Provincial Departments of Health –

  • Eastern Cape has placed orders and are awaiting delivery. They will also manage wheelchair supply as a project to reduce this waiting list.
  • KwaZulu-Natal has placed orders and is awaiting delivery which will clear the waiting list.
  • Limpopo will arrange that deliveries to take place at district offices for hospitals to collect nearby, thereby reducing the turnaround time.
  • Mpumalanga will prioritize procurement early in the beginning of the financial year. The waiting list developed because of expiry of relevant transversal contract.
  • North West will increase the budget in the 2023/24 financial year.
  • Northern Cape commits to place orders by end April 2023.
  • Gauteng is yet to advise

c) We are informed by the provinces that the backlog will be reduced by the end of July 2023.

END.

23 March 2023 - NW692

Profile picture: Hlengwa, Ms MD

Hlengwa, Ms MD to ask the Minister of Health

(1)With regard to the R23 million allocated to his department by the National Treasury, what portion of the allocated amount will be dedicated to employ more skilled and/or specialised health workers to capacitate the crumbling health system and the environmental pressures experienced by health workers; (2) whether, considering that the healthcare sector has been affected by load shedding and various clinics around the Republic have raised concerns about their ineffectiveness to carry out their duties as a result, funds will be allocated to providing more power back-up to the affected institutions; if not, why not; if so, by what date?

Reply:

1. I am pleased to inform honourable member that the Department developed and published (in February 2021), a 2030 Human Resources for Health Strategy that serves as a guideline of the Human Resources Agenda for the Public Health sector at various levels of care.

2. The modelling undertaken in the development of the 2030 HRH Strategy, indicates a current shortfall of skilled health professionals in South Africa hence the strategy makes a call for investing in the health workforce to address human resources deficits and inequalities across provinces and between private and public health sectors. However, its implementation has been a challenge due to stringent budgets.

3. To date, with the acknowledgement of the available limited resources in the public service generally, the Department has managed to close the vacancy-rate gap for healthcare related posts to 12.4% and administration positions to 11.80%, respectively, as at the 30 September 2022, across all provinces.

4. The Department further managed to allocate guaranteed funding/budget for the statutory positions of medical internship and community service personnel through the equitable-share and the Human Resources Training Grant (HRTG).

5. Further to the above developments, to address shortages and to ensure the provision of optimal healthcare services, Provincial Departments of Health are implementing plans that amongst others include:

  • Prioritisation of the posts in the Annual Recruitment Plan – where funding permits
  • Prioritisation of the posts for conditional grant funding
  • Filling of replacement posts considered and approved weekly
  • Employment of health professionals on contract bases to strengthen capacity
  • Prioritization of these contract employees for permanent employment where funding permits at the end of their contracts
  • Awarding of bursaries yearly to internal and external candidates to study further in various disciplines where there are shortages
  • A dedicated Registrar Programme to train and produce specialists
  • Provision of the internship and community service programme.

END.

23 March 2023 - NW611

Profile picture: Clarke, Ms M

Clarke, Ms M to ask the Minister of Health

(1)Whether he has been informed of allegations against a certain person (name and details furnished) for (a) the misuse of State funds, (b) the contravention of procurement and tender procedures, (c) threatening behaviour towards staff and (d) the misuse of office vehicles; if not, why not; if so, (2) whether he has launched an investigation in this regard; if not, will he launch an investigation; if so, what are the relevant details?

Reply:

My office was informed by the Board of the Office of Health Standards Compliance (OHSC) of the various allegations against the Chief Executive Officer (CEO) in August 2022, which contained inter alia allegations as set out in the Honourable Member’s.

2. The functions of the OHSC are under the control of the Board, and the Board is the Accounting Authority of the Office. I am informed by the OHSC that the allegations were investigated by the Human Resources and Remuneration Committee; Audit, Risk and Finance Committee and the Executive Committee of the OHSC Board in terms of the applicable Grievance and other policy prescripts, following which the Board considered the reports.

Following the above investigation, the Board did not find substance in the allegations against the CEO, relating to (a) the misuse of State funds, (b) the contravention of procurement and tender procedures, (c) threatening behavior towards staff and (d) the misuse of office vehicles.

Based on the investigation and findings of the Board I do not see the need for the Minister to repeat such an investigation which would come with an additional cost.

END.

23 March 2023 - NW593

Profile picture: Ismail, Ms H

Ismail, Ms H to ask the Minister of Health

What percentage of (a) matriculants and (b) teachers chose to be vaccinated during the pandemic?

Reply:

The Electronic Vaccination Data System (EVDS) does not make provision for the classification of an individual as a matriculant, teacher or any other occupation.  We are therefore unable to provide the requested data.

As at 13 March 2023 a total of 2 186 819 people between 12 and 17 years of age had been vaccinated (primary schedule) out of a total of 6 239 794 minors in this age bracket (35,04%).

During the essential service vaccination period personnel of the public and private basic education sector were vaccinated but it was made clear that that time that no differentiation was made in data collection that would make it possible to identify teachers separately.

END.

23 March 2023 - NW612

Profile picture: Clarke, Ms M

Clarke, Ms M to ask the Minister of Health

Considering that the SA Health Products Regulatory Authority is blocking companies (details furnished) from importing Meloxicam BP for compounding purposes, despite the fact that SAHPRA’s reasoning is apparently based on a faulty interpretation of the law (details furnished), what are the reasons that SAHPRA is blocking the importing of Meloxicam BP for compounding purposes?

Reply:

According to the South African Health Products Regulatory Authority (SAHPRA), the importation of Meloxicam was not blocked. Meloxicam is a scheduled substance, and the importer of these substances requires an importation licence as per Section 22C (1) (b) of the Medicines Act and the related regulations.

The SAHPRA processes all applications in accordance with the legislation indicated above and has presence at the regulated ports of entry in line with Regulation 6 of the Regulations, to ensure that the importers of scheduled substances comply with the law. As per the table below there is no Meloxicam detained as per the list of importers provided in the question:

TABLE 1: IMPORT LICENCE APPLICATION STATUS OF FURNISHED COMPANIES

No

Company

Import Licence Application Status

Currently Detained API

Expected Outcome date

1

DB Fine Chem/ Spec

Application finalised recently Licence to Import/distribute scheduled substances as per approved list and pharmacies offering compounding services may access via this or similarly licenced facility.

None

N/A

2

Marsing

Licence being finalised, due to name change and organisational ownership changes over the past few years, they were delaying on application processes. This has now been resolved.

None

N/A

3

Idexis

No application received

Under review Vitamin K2 (ORTIA)

Before 9/03/2023

4

Compounding Pharmacy of SA

No application received

None

N/A

5

Fagron

No application received

None

N/A

6

Rowan Management

No application received

None

N/A

7

V Tech

Licence application under process due to other considerations and an inspection to take place

Under review prednisolone (ORTIA)

Before 9/03/2023

8

Acupharm

No application received

Under review Famotidine (ORTIA)

Before 9/03/2023

9

Lycoderm

No application received

Under review Vit K1(through Multichem Sourcing ORTIA)

Before 9/03/2023

10

Lenbury

No application received

None

N/A

11

Kyron

No application received

Under review Petcam (ORTIA)

Before 9/03/2023

12

Avanti

No application received

None

N/A

13

Vets Focus

No application received

None

N/A

END.

17 March 2023 - NW531

Profile picture: Thembekwayo, Dr S

Thembekwayo, Dr S to ask the Minister of Health

NATIONAL ASSEMBLY FOR WRITTEN REPLY QUESTION NO. 531 DATE OF PUBLICATION IN INTERNAL QUESTION PAPER: 03 MARCH 2023 (INTERNAL QUESTION PAPER NO. 06) Dr S S Thembekwayo (EFF) to ask the Minister of Health: [77] [Question submitted for oral reply now placed for written reply because it is in excess of quota (Rule 137(8))]: Whether his department conducted any internal assessment on the safety of any of the COVID19 vaccines administered to South Africans; if not, why not; if so, has he found evidence of any elements of the vaccine that may put the lives of persons at risk? NW576E REPLY: Adverse Events Following Immunisation (AEFI) and safety concerns in terms of contraindications, special precautions and warnings are reviewed and included in the product Information leaflet. All potential risk factors are outlined in the product information leaflet and the clinician/health care provider prescribing the vaccine is thereby informed. If there are critical concerns/risks, the product will not be registered and will not be made available to public. The responsibility for pharmacovigilance and surveillance is ultimately with the regulator, SAHPRA. All clinicians and the public themselves have been encouraged to report both side effects and adverse events. There is ongoing assessment of safety of all medicines and vaccines. This information is shared globally so that all countries can combine their experiences and determine actions where appropriate. In the case of the Covid-19 vaccines in use in the country there is a great deal of information available, it is included in the product information. There are known rare adverse events, just as rare side effects are known for all medicines. The evidence is that no elements of the two Covid-19 vaccines may put the lives of persons at risk any more that another medicine. There is however evidence that the vaccines improve immunity and protect the vaccinees from severe infection. END.

Reply:

Adverse Events Following Immunisation (AEFI) and safety concerns in terms of contraindications, special precautions and warnings are reviewed and included in the product Information leaflet. All potential risk factors are outlined in the product information leaflet and the clinician/health care provider prescribing the vaccine is thereby informed. If there are critical concerns/risks, the product will not be registered and will not be made available to public.

The responsibility for pharmacovigilance and surveillance is ultimately with the regulator, SAHPRA. All clinicians and the public themselves have been encouraged to report both side effects and adverse events. There is ongoing assessment of safety of all medicines and vaccines. This information is shared globally so that all countries can combine their experiences and determine actions where appropriate.

In the case of the Covid-19 vaccines in use in the country there is a great deal of information available, it is included in the product information. There are known rare adverse events, just as rare side effects are known for all medicines. The evidence is that no elements of the two Covid-19 vaccines may put the lives of persons at risk any more that another medicine. There is however evidence that the vaccines improve immunity and protect the vaccinees from severe infection.

END.

17 March 2023 - NW564

Profile picture: Jacobs, Dr KL

Jacobs, Dr KL to ask the Minister of Health

Whether his department has conducted a study to evaluate the effectiveness of the Central Chronic Medicines Dispensing and Distribution programme which brings medication closest to the users and reduces congestion in health facilities; if not, why not; if so, what are the relevant details?

Reply:

An evaluation was conducted and finalised in August 2019, just prior to COVID-19.

The report found that:

“The evaluation findings suggest that the Central Chronic Medicines Dispensing and Distribution (CCMDD) is overwhelmingly believed to be the National Department of Health’s (NDoH’s) most successful intervention implemented during NHI Phase 1. This has been identified as a flagship programme, and for this reason, there are numerous valuable lessons to be learned from its implementation. These lessons will only apply to the continuation of the CCMDD programme but can be useful for the continued implementation of other interventions. Specifically, lessons around the issues of contracting private service providers, which has been communicated by the NDoH to be a key component of NHI Phase 2.”

“On balance, it is evident that CCMDD has indeed achieved its immediate aims of decongesting facilities, which helps improve the availability of Health Care Practitioners’ time and, as a result, improve health outcomes. The success is largely reflected in the successful scale-up of the programme beyond the pilot districts and beyond the expectations of NHI Phase 1 implementation plans.”

“Stakeholders also observed this intervention was well integrated with other interventions, and this integration was evidenced by information sharing between the CCMDD programme and the WBPHCOTs.”

Like any other programme, funding is critical to the success of CCMDD. While the programme had limited donor funding initially it is now funded mostly from a portion of the NHI conditional grant.

During COVID-19 patients were able to collect their chronic medication from CCMDD Pick-up-Points (PUPs) outside of health facilities without undue exposure to the virus. During that time script periods were extended and patients were required to return less frequently to collect their medicines. This lesson has been adopted as current practice to extend the capacity of the CCMDD and to improve access to medicines for patients.

END.

17 March 2023 - NW517

Profile picture: Shaik Emam, Mr AM

Shaik Emam, Mr AM to ask the Minister of Health

What (a) are the latest developments in a certain matter (details furnished) and (b) steps is his department intending to take to prevent any unnecessary escalation of cost being incurred by the taxpayers as a result of the matter?

Reply:

(a) According to the KZN Province, Dr Shaheem Seedat who was employed at Mahatma Gandhi Memorial Hospital in eThekwini, KZN, was suspended and charged for allegedly negligence (causing the death of a motor vehicle accident patient).

On 18 March 2016 he was then charged and subsequently found not guilty.

On 25 February 2019, Dr Seedat issued summons (claim) against the Department of Health, KZN for reputational damage in the sum of R20 650 000.00. In his summons he alleged that during 2016 the MEC for Health made a statement to various media /news that he was suspended and being investigated for the charge of misconduct. According to him such newspaper or social media statements were wrongful and defamatory, causing reputational damage.

The Provincial Department of Health defended the case through the office of the state attorney. The Parties have exchange pleadings. The state attorney reports that the Plaintiff (Dr Seedat’s attorneys) wanted to amend their summons.

At this stage there is no date for the trial yet. The Plaintiff (Dr Seedat) will have to apply for it. The notice to amend is still awaited.

(b) The Department of Health, KZN (the employer) is obliged to investigate any alleged misconduct by its employees. The acquittal does not mean that misconduct did not occur. According to the Department of Health, KZN, the claim for damage in the sum of R20 650 000.00 by Dr Seedat is not justified and as such must be defended.

END.

17 March 2023 - NW660

Profile picture: Mohlala, Ms MR

Mohlala, Ms MR to ask the Minister of Health

In light of the recent international Cholera outbreak, what are the details of the immediate steps his department has taken in each province to raise awareness amongst the public about the prevention and management of cholera?

Reply:

Steps the department has taken to raise awareness amongst the public about the prevention and management of cholera.

After the WHO reported that the cholera outbreak had occurred in Malawi and Mozambique, and other countries in the SADC regions, the National Department of Health alerted all the provinces about the cholera outbreak. The provinces were requested to use the risk assessment and contingency plan tools to assess their capacity for preparedness and readiness for cholera outbreak. The National Department of Health met with the provinces to discuss the plans and actions required in preventing and controlling the spread of cholera. Steps that were taken to raise awareness amongst the public about the prevention and management of cholera are outlined below as follows:

a) Prevention and Control

The National Department of Health has activated the Multisectoral National Outbreak Response Teams (MNORT), which includes members from the National Department of Health, National Institute for Communicable Diseases (NICD), provinces and the World Health Organization (WHO). The focus areas include surveillance; water, sanitation and hygiene; social mobilisation; Risk Communication and Community Engagement. The MNORT meetings are held on weekly basis (Fridays) to discuss the ongoing cholera outbreak in the country.

  • A public announcement was made to inform and alert the public about the outbreak of cholera.
  • All provinces received cholera guidelines and case investigation forms.

b) Community Engagement

Community engagements were conducted in all provinces, and distribution of Information, Education, and Communication (IEC) pamphlets and posters to teach the public about potential risks, symptoms of cholera, precautions to take to avoid cholera, when and where to report cases and to seek immediate treatment when symptoms appear continues to take place.

Awareness was raised about prevention through:

  • Development and distribution of posters and flyers
  • Giving health talks on community radio stations
  • Cholera prevention and management messages were shared using departmental social media.
  • Continuous health education is conducted in health facilities.

END.

17 March 2023 - NW565

Profile picture: Jacobs, Dr KL

Jacobs, Dr KL to ask the Minister of Health

What progress has been made in the trials for a cure for the Human Immunodeficiency Virus and the Acquired Immunodeficiency Syndrome in which the Republic has participated in several international trials for a cure to the pandemic?

Reply:

Various scientific institutions and groups have been involved in the collaborative work on the cure for the Human Immunodeficiency Virus (HIV) and the Acquired Immunodeficiency Syndrome (AIDS). All scientists agree that finding a cure is far more complex because no one has ever been cured of HIV and AIDS and as such correlates of protection are not known. There is some other work towards a cure that include people who go on structured treatment interruption after receiving some intervention and South Africa is involved in these studies. There is also an investigation of the use of Indigenous Knowledge System (IKS) or products derived from indigenous plants that have antiviral activities and claims to cure HIV. There is, further, an on-going work that is designing appropriate studies to investigate many claims of cure for HIV and AIDS, which will probably be structured treatment interruption based.

In the meantime, South Africa has participated in various HIV vaccine efficacy studies such as Phambili, Uhambo, Imbokodo, and Antibody Mediated Prevention (AMP). The outcomes of these studies have found that the vaccines that were tried are not effective against the virus. These trials were critical to our endeavor to find an effective HIV vaccine, hence their findings have led us to pursue two alternative pathways:

  • A programme of experimental HIV vaccine trials to improve immunogenicity using an approach to iteratively develop and improve both bnAb and T-cell targeting vaccines and that.
  • The next (5) five years the country will be assessing the role of utilizing broadly neutralizing monoclonal antibodies as part of HIV prevention strategy.

We are also evaluating these vaccine approached in HIV exposed uninfected infants to try and prevent breastmilk transmission.

It is critical to collaborate with international partners because the costs of these trials are prohibitive.

While these efforts are ongoing, everyone must be mobilized to support the Antiretroviral programme which has demonstrated achievement in viral suppression when and where there is a strong adherence to treatment.

END.

17 March 2023 - NW522

Profile picture: Hlengwa, Ms MD

Hlengwa, Ms MD to ask the Minister of Health:

In view of the Republic being a water scarce country leading to water restrictions and supply being imposed on hospitals and clinics around the Republic, creating an unhygienic environment contrary to requirements of the Occupational Health and Safety Act, Act 85 of 1993, and thereby contributing to the spread of infectious diseases, what (a) steps has his department taken to ensure that healthcare facilities have adequate risk assessment plans for water shortages and (b) plans does his department have to mitigate the devastating effects of water cuts at healthcare facilities?

Reply:

(a)-(b) At Primary Health Care level, the department has an Ideal Health Facility tool that is used to determine the number of health facilities that have functional piped water and the number of health facilities that have emergency water supply.

Each health facility is required to have both functional piped water and emergency water supply kept in water tanks connected to the water reticulation system in the health facility. There is also further arrangement with municipalities that in case of the emergency water tankers running empty during drought seasons, the municipality brings water by means of water tanker trucks to fill up emergency water tanks at the health facility.

END.

17 March 2023 - NW644

Profile picture: Marais, Ms P

Marais, Ms P to ask the Minister of Health

Whether he has been informed that in the Mangaung Metropolitan Municipality, Emergency Medical Services (EMS) do not arrive to collect patients when they are called; if not, what is the position in this regard; if so, what are the relevant details?

Reply:

I am aware that there were concerns raised by communities regarding provision of ambulances services around Botshabelo and Mangaung in 2022 in Free State. I am also aware that the MEC of Health in the Free State has also responded to some of the communities and have acceded to some of these challenges in this regard.

Pertaining to this particular incident in the Mangaung Metropolitan Municipality where an ambulance did not arrive to collect a patient when an emergency call was made to the Emergency Communication Centre, I was not informed of this. The lack of details on this particular matter makes it difficult to make an enquiry.

I have however been informed by the province that the Public Emergency Medical Services in Mangaung Metropolitan Municipality currently operates with 26 ambulances distributed as follow:

  • Bloemfontein 11
  • Botshabelo 6
  • Thaba Nchu 5
  • Wepener 1
  • Dewetsdorp 2
  • Soutpan 1

The public also has an opportunity to report the matter through the Free State Department of Health’s complaints system.

END.

17 March 2023 - NW521

Profile picture: Hlengwa, Ms MD

Hlengwa, Ms MD to ask the Minister of Health

With reference to the reported healthcare collapse in the Republic, what (a) is the justification of the situation of junior doctors who are bursary holders and have not been placed in positions by the State, but are being released from their contractual obligations by the Gauteng Department of Health and (b) plans does his department have to address the dire shortage of doctors in the Republic?

Reply:

I would first like to set the record straight that as much as there are challenges in Health sector, it should be noted that the health sector has not collapsed.

a) I have been informed by the Gauteng Department of Health that it is unable to place junior doctors who are bursary holders due to budget constraints. However, there is a process underway to prioritize the human resources needs to place them in institutions across Gauteng.

b) Due to general budget cuts that affects the Cost of Employment (CoE) in the public health sector, there is a systematic process of approving funding and advertisements of posts by Accounting Officers in consultation with Provincial Treasuries supersedes filling of vacant posts to avoid exceeding Cost of Employment (COE) budgets. Therefore, the Department prioritised the filling of the critical and scarce skills within the available budget.

Across all provinces, both clinical and non-clinical posts are continuously identified and vacancies are filled through block adverts and recruitment throughout the year in response to the service demands.

END.

17 March 2023 - NW567

Profile picture: Xaba, Mr NV

Xaba, Mr NV to ask the Minister of Health

What has been the (a) impact of the floods on the delivery of health care services and (b) measures has he put in place to mitigate the impact of the ravaging floods that recently hit the Eastern Cape, Gauteng, KwaZulu-Natal, Limpopo, Mpumalanga, Northern Cape and North West to the extent that a National State of Disaster has been declared?

Reply:

a) There has been minimal disruption to the delivery of health care services in all flood affected provinces within the public sector. However one private hospital in Komani, Eastern Cape was severely affected by flooding where our public sector Emergency Medical Services assisted with transferring of in-patients to nearby healthcare facilities.

The rendering of Primary Health Care services continued unaffected and assistance was also provided to the displaced community members in temporary shelters where necessary. Temporary shelters were inspected daily to monitor for water-borne diseases. No outbreaks or cases of food borne illness directly attributable to the floods were reported. Medication distribution was also not affected.

b) The Department of Cooperative Governance and Traditional Affairs (COGTA) through the Disaster Management Act of 2002 is responsible for disaster management however the Department of Health has also put several health measures in place at national, provincial and district levels to mitigate for the impact of floods as follows:

i) Governance

  • The National Department of Health(NDOH) participates in the inter-sectoral national structures, the National Disaster Management Centres (NDMC); linking with the provincial Departments of Health for national oversight and support.
  • The provincial Departments of Health are represented at Provincial Joint Operation Centres (ProvJOC), Provincial Disaster Management Centres (PDMC) and/or local Disaster Management Centres, as activated within the respective provinces for effective and efficient response.
  • EMS is placed on high alert to provide emergency response as and when required. EMS from unaffected provinces gets mobilized to assist affected provinces when needed and this is facilitated by NDOH.
  • Urban search and rescue teams are on standby to assist affected provinces with rescue and medical personnel.

ii) Hospital Services

iii) Both public and private hospitals are alerted to receive patients in all affected areas in case of diversions as and when needed. If necessary, inpatients will be transferred to unaffected hospitals.

iv) Primary Health Care(PHC) Services If a PHC facility is affected, patients will be directed to an unaffected PHC facility, or mobile clinics will be utilized. PHC services may also be provided in temporary shelters.

v) Environmental Health Services (EHS)

National and Provincial EHS officials provide oversight and support. The respective local government EHS will undertake water quality monitoring and ensure appropriate sanitation measures are adhered to. Temporary shelters, if established, will be inspected by teams from the Environmental Health Units daily.

vi) Communicable Disease Control, COVID-19, Malaria and Zoonotic Diseases

  • The respective Outbreak Response Teams at district, provincial and national, are placed on high alert to monitor affected areas and are on standby to respond to any water borne / communicable disease that may arise.
  • The National Institute for Communicable Diseases (NICD) heightens surveillance for COVID-19, malaria and zoonotic diseases in the affected areas.

vii) Health Promotion & Nutrition

Awareness on water safety and communicable diseases is initiated within the communities as needed. Small scale water purification, safe food handling and keeping and monitoring of food is also done to ensure prevention of food poisoning and communicable diseases.

viii) Food Control

  • Food Control makes food safety Information Education and Communication(IEC) material available to respective EHS and Health Promotion teams to create awareness as needed.
  • EHS gets also support in terms of inspection of donated foodstuffs to ensure safety, and record keeping as and when required.

ix) Forensic Pathology Services (FPS)

FPS function is to remove bodies of flood victims in close collaboration with SAPS in affected areas.

x) Pharmaceuticals

Medication distribution will be monitored for disruptions and alternate distribution methods are applied.

xi) Risk Communication and Community Engagement

Media releases are undertaken on all platforms as and when required. Monitoring of local media clips, news and social platforms is also ongoing.

Additional technical expertise is also available and gets deployed where needed.

END.

17 March 2023 - NW566

Profile picture: Havard, Dr X

Havard, Dr X to ask the Minister of Health

With regard to the COVID-19 pandemic that revealed glaring shortages of human resources for health care globally, particularly in the category of nurses, what measures has his department put in place to increase the pool of human resources for health care in the Republic?

Reply:

The shortages of human resources for health are a global phenomenon and South Africa has not been spared from this challenge. The human resources challenge was particularly glaring as the country grappled to manage and contain the Covid-19 pandemic.

The human resource for health shortfall is well recognized by the country’s 2030 Human Resources for Health (HRH) Strategy which makes a strong case for significant additional investment in the health workforce to improve health services access, quality, and equity.

In increasing the pool, the HRH Strategy provides some insights into the additional numbers of health workers needed Hence a case is also made for aligning health workforce education and training with the health system’s needs.

Specific to a pool of nurses, a baseline audit to quantify gaps between existing supply and existing needs for all categories of nurses including nurse specialists has been concluded. This will guide areas of training required to increase the pool.

In order to enhance services in the overstretched public health sector, particularly with regard to South Africa’s response to the Covid-19 Pandemic, the department appreciated the introduction of the Covid-19 Grant and was able to inject an additional 6 688 health care workers (that included 3 460 nurses and 409 doctors) into the System on a contract basis

A further 7 583 (with 2 605 Nurses and 2060 Doctors) health professionals were allocated to do community service in health facilities to commence duty from 1 January 2023.

END.

17 March 2023 - NW530

Profile picture: Thembekwayo, Dr S

Thembekwayo, Dr S to ask the Minister of Health

Whether he has been informed of the alleged practice of the Witbank TB Specialised Hospital, in the Nkangala region of Mpumalanga, of refusing to treat newly diagnosed TB patients and directing them to Bongani Regional Hospital; if not, what is the position in this regard; if so, what steps has he taken to ensure that the hospital is able to provide treatment to everyone who goes to it for treatment?

Reply:

No, I was not aware of any refusal by the Witbank TB Specialised Hospital to treat newly diagnosed TB patients and directing them to Bongani Regional Hospital.

The Mpumalanga Province has been reorganising the service platform, due to demands in the Province. This has resulted in the repurposing of Witbank TB Specialised Hospital to be the internal medicine unit to support Witbank Provincial hospital. The repurposing of the hospitals means that Bongani Hospital is the new DR-TB referral site to take over the clinical management of complicated DR-TB patients for the entire province. All district hospitals are still responsible for the management of the DS-TB patients.

END.